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1. CANCER PHYSIOPATHOLOGY 
 
A normal cell in the body will grow and divide in a controlled way in order to 
produce more cells keeping the body healthy, in this manner when a cell became old 
or damaged this cell will initiate a programed dead and will be replaced with a new 
one, however, sometimes cells suffer small mutations in its genetic material that will 
affect the growing and division processes and that could lead to an uncontrolled cell 
proliferation (2).  
Cancer is a multistep process characterized by an uncontrolled cell proliferation 
usually implicated by several changes in the genome, which usually lead to a 
recessive function of tumour suppressor genes or to a higher production of 
oncogenes that will transform normal cells into a progressive evolution from 
premalignant cells into invasive cancers(3) 
Different types of damaged cells will induce different types of cancers but all types 
of cancer will have some common processes(2).  In all cases tumorigenesis occurs 
when the anticancer mechanisms like apoptosis, programed cell death or DNA 
reparation fails. Scientific advances made over the past decades, both in animals and 
in vitro studies in different organs, suggest that tumorigenesis has common 
intermediate steps(3).  
In 2000, Hanahan and Weinber suggested that tumorigenesis is controlled by six 
essential alterations that are common to all types of cancers which are: self-suffiency 
in growth signals, insensitivity to anti-growth signals, evading apoptosis, limitless 
replication, sustained angiogenesis and tissue invasion and metastasis – Figure 1(3).  
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Figure 1 - Hallmarks of cancer - The six alterations proposed to the development of 
tumourigenesis. (Figure adapted from (3)) 
Usually these alterations are controlled by the maintenance genome under the 
control of complex mechanisms. Additionally, cell cycle checkpoints in mitosis 
assure the identity of the DNA information. Thus, investigators believed that tumour 
cells developed increased mutability due to genomic instability by decreasing the 
functions of the caretaker systems, like the p53 tumour suppressor protein (3). In this 
way when all of these systems tend to fail normal cells will grow in an uncontrolled 
way leading to possible cancer(2).  
Later in 2011, progresses in cancer research added, to the previous six alterations in 
the cells, the ability to evade immune destruction and the capability to reprogram the 
cellular metabolism. In fact, it was also discovered that a tumour is not only a mass 
of proliferative cells, but a complex microenvironment composed by different cell 
types with heterotypic interactions - Figure 2(4).  
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Figure 2 – Tumour Microenvironment - Example of a tumour microenvironment composed 
with different types of cells and different functions (figure from(4)) 
Different types of cancer will provoke different signs and symptoms in patients 
according with the site of the cancer, however most of the patients will experience 
common general signs and symptoms as fever, fatigue, weight loss, pain, skin 
changes, unusual bleeding and presence of new tissue masses(5). 
Nowadays there are several tests like CT and MRI scans, biopsies of the tumour 
sites and blood tests for tumour markers specifics that allow the physicians to have a 
better diagnose of the stage, location and size of the tumours(6). 
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2.  HEAD AND NECK CANCERS 
Head and neck cancers include a diverse group of salivary gland neoplasms and 
squamous cell cancers from the mucosa’s of the aero digestive tract, however there 
are some unique cancers in this region like nasopharyngeal carcinomas, Sino nasal 
undifferentiated carcinomas, esthesioneuroblastoma and thyroid cancers(5). 
The majority of head and neck cancers  - 95% -  are squamous cell carcinomas 
(HNSCC) that occur in the mucosa and can be divided according six anatomic 
regions: oropharynx, hypopharynx, larynx, oral cavity, nasopharynx and paranasal 
sinus – Figure 3 and Table I (7).  
 
Figure 3 - Head and Neck anatomy 
Specific signs and symptoms of this types of cancers includes hoarseness or change 
in voice, white or red patches in oral cavity, unusual bleeding or pain in the mouth, 
masses in head or neck area, persistent pain chewing or swallowing and persistent 
nasal obstruction or congestion(5). 
Despite the low incidence rate, the high mortality rate is in most of the cases 
associated with the late diagnosis (8). In fact, most of the diagnosed cases are 
invasive tumours involving cervical lymph nodes and in some cases with local or 
distant metastases (9). 
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Table I- Different types of cancers from head and neck (only nasopharynx cancer is not 
Squamous Cell Carcinoma) (Adapted from ()) 
Different types of head and neck cancers 
Oral Cavity Floor of the mouth 
Tongue 
Lips 
Buccal surfaces 
Gums 
Hard Palate 
Oropharynx Papillae 
Tonsils 
Epiglottis 
Pharyngeal Walls 
Soft Palate 
Hypopharynx Piriform sinus 
Lateral and Posterior pharyngeal walls 
Posterior faces of larynx 
Larynx Vocal Chords  
Larynx 
Subglottic and Supraglottic  
Thyroid 
Cricoid and arytenoid cartilages 
Paranasal 
sinuses 
Maxilla 
Ethmoid, sphenoid and frontal sinuses 
Nasal Cavity 
Nasopharynx Mucosal surfaces and structures of the cavity behind 
nasal passages 
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2.1 Epidemiology 
According to the International Agency for Research on Cancer (IARC), head and 
neck cancers (HNC) account for about 5% of all of the human cancers in Portugal 
has we can see in Table II. These data show that despite the relative low incidence, 
there is a higher incidence in men when compared to women. Some results are 
observed for mortality rates, despite the low incidence almost 50% of the patients 
die and therefore this is considered an important public health problem(8).  
 
Table II - Incidence and Mortality rates by gender in Portugal for Head and Neck cancers 
according to IARC (4). 
Cancer 
Incidence 
(number of cases per 
100,000) 
Mortality 
(number of cases per 
100,000) 
Men Women 
Both 
gender 
Men Women 
Both 
gender 
Lip, oral 
cavity 
3,2 1,3 2,4 1,9 0,7 1,4 
Nasopharynx 0,3 0,2 0,3 0,3 0,1 0,2 
Other 
pharynx 
1,7 0,1 1,0 2,1 0,2 1,3 
Larynx 2,4 0,1 1,4 2,7 0,2 1,7 
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2.2 Aetiology  
IARC identified almost 500 agents that are associated with the development of 
cancer in humans, which can be divided in two different groups according to their 
hazard risk. These agents were selected based on evidence of human exposure and 
evidence or suspicion of carcinogenity(10).  
The recent evolution of genetics has lead to the development of tools that could help 
clinicians to detect, diagnose and predict the development and the behaviour of a 
specific cancer. Recent molecular techniques have provide us a better knowledge on 
the carcinogenesis on HNSCC where it’s described several epigenetic and genetic 
alterations in invasive cancers – Figure 4 (11). 
Head and neck cancer is considered to be multifactorial and its development is 
associated with several chromosomal abnormalities besides other co-factors related 
with behavioural risks that will induce damages in DNA such as: alcohol and 
tobacco(10), chewing of betel quid (seeds of the betel palm and tobacco wrapped in 
betel leaf), diet deficiencies (12) oral hygiene and viral infections (13), salted fish 
and smoking wood dust(10).  
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Figure 4 - progression and molecular changes in head and neck cancers that suspects to 
transform a normal epithelium into an invasive carcinoma (figure from (10) 
3. RISK FACTORS 
Nowadays there are several external factors to the human being that can increase the 
probability of an individual to develop cancer, despite this factors influence in the 
cancer development they do not cause cancer directly once there is several persons 
exposed to several risk factors that never develop any type of tumour or neoplasia. 
REF head and neck: squamous cell carcinoma: an overview 
One of the best ways to prevent head and neck cancer is to avoid the recognised risk 
factors and to visit a dentist regularly since examination in the oral cavity can 
identify pre-cancerous lesions that will allow the physicians an easier treatment than 
a stage 3 or stage 4 cancers(12, 14). 
 
3.1 Alcohol and Tobacco consumption as Risk factors  
Tobacco and alcohol are the major environmental risk factors for head and neck 
cancers due to their mutagenic effect(15). Tobacco is composed by nitrosamines (N-
nitrosonornicotine (NNN), polycyclic aromatic hydrocarbons (PAH) and 4-
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(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)) (12) type I that are 
considered to be carcinogenic agents(10). Moreover alcohol is metabolized in 
acetaldehyde by alcohol dehydrogenase and acetaldehyde has proved to have a 
mutagenic effect on DNA(16). However literature has shown that tobacco and 
alcohol carcinogenic effect is dose-dependent, and consumption in small doses 
might not increase the risk of oral cancer substantially(12). 
The consumption of alcohol and the exposure to tobacco in high doses promotes 
damages in the DNA that can induce the development of cancer. Recent studies with 
spectral karyotyping, comparative genomic hybridization and fluorescent in situ 
hybridization (17) have shown several chromosomal alterations in HNSCC patients 
(gain of 1q, 3q, 5p, 7q, 8q, 9q, 11q, 12p, 14q e 15q; and loss of 1p, 3p, 4p, 5q, 8p, 
10p, 11q, 15q and 18q) (18-21). 
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3.2  Viral mechanisms as Risk Factors 
Virus can be defined as an intracellular parasite with extracellular phase dependent 
on the host cell functions and metabolism and with DNA or RNA genome encased 
in a protective shell.  
Generally viruses cycle is composed by three stages: the infection, in which the virus 
penetrates the cell trough the attachment mediation of the viral surface proteins to 
the cellular receptors; the replication, in which a viral protein inactivates proteins 
like p53 or Rb in preventing cell apoptosis and the lysis in which there is a cell 
rupture and the release of new replicated viruses (22).  
Virus and parasites contributes to oncogenesis accelerating mutations rates and 
enhancing proliferative signals through inflammation. Several viruses with different 
transmissions are associated with different types of cancers – Table III(23). 
Table III - Correlation between different viruses and different types of cancers. The cancers 
in parentheses are a possible correlations. (Figure from(23). 
Virus Cancer Transmission 
HPV Cervical, penile, rectal, oropharyngeal, 
Head and Neck 
Sex, transiently by 
saliva 
HBV Hepatocellular [cholangiocarcinoma] Sex, breast milk 
HCV Hepatocellular [cholangiocarcinoma] Sex 
EBV Burkitt's lymphoma, nasopharngeal, 
posttransplant proliferative disease 
[acute 
lymphoblastic leukaemia, breast, gastric 
carcinoma, ovarian] 
Sex, saliva 
Cytomegalovirus [Brain] Saliva, sex 
HTLV-1 Adult T cell leukaemia Sex, breast milk 
Merkel cell 
polyomavirus 
Merkel cell cancer Probably saliva 
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Off all viral infections, the most frequent carcinogenic viruses are Epstein-Barr virus 
(EBV), and human papilloma virus (HPV)(13). According to recent studies EBV 
contributes to oncogenesis and is commonly associated with B-cells diseases and 
usually detected in nasopharyngeal carcinomas, Hodgkin’s disease, Burkitt’s 
lymphoma and post-transplant B cell lymphomas (24).  
HPV is considered to be a potential risk factor for head and neck cancer. This virus 
can be observed in early tumorigenesis, and more recently it has been suggested that 
HPV is a marker of a favourable prognosis (25). 
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Human papilloma virus and head and neck cancer 
In 1949, papillomaviruses were first reported in a human mole visualized by electron 
microscopy and later in 1963 its genome was unravelled. Studies have contributed to 
the theory presented in early 70’s that papillomaviruses could be involved in the 
aetiology of cervical cancer (26). Later in 1980s it was possible to isolate HPV types 
6 and 11 from genital warts and HPV types 16 and 18 from cervical cancer biopsies 
confirming the role of HPV in the development of these lesions. Recent data 
demonstrate that HPV 16 is linked to other widespread human tumour types as the 
oropharyngeal cancer (26).  
 
 Structure and regulation of HPV  
The HPV is a double stranded DNA virus and his genome contains 7200 to 8000 
base pairs (17).  The viral particle is approximately 55 nm and is composed by a 
capsid composed by 72 capsomeres (histone-like proteins): the major capsid protein 
is encoded by L1, a protein highly conserved amongst the different types of 
papillomavirus; and the L2 that is more variable(26).  
  
Most of the papilloma virus sequences can be found in online databases such as 
EMBL and GenBank(27). 
The genome of HPV can be divided in three different regions; an early region (E) 
from E1 to E7 responsible for the lytic cycle, DNA replication and regulatory 
Figure 5 - HPV Genome HPV 
genome - It is possible to 
distinguish the different viral 
proteins in Early and Late 
regions and the Long Controlled 
Region (figure from(1)) 
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functions; a late region (L) divided in L1 and L2 that encodes structural proteins and 
compose the viral capsid and a long controlled region (LCR) also known as 
upstream regulatory region positioned between E6 and L1 as showed in figure 5 (26, 
27). 
According to the oncogenic activity of HPVs these viruses were classified into 
different groups(28): low-risk HPVs (type 6, 11, 13, 40, 42, 43, 44, 54, 61, 70, 72, 
81 and 89); in probable high-risk HPVs (type 26, 53, 66, 68, 73 and 82); in high-risk 
HPVs (type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59); and in undetermined-
risk HPVs (type 30, 32, 34, 62, 67, 69, 71, 74, 83, 84, 85, 86, 87, 90 and 91)(29). 
 
Human Papillomavirus viral proteins  
The early region of HPV genome is responsible for the regulator and replication 
functions of HPV proliferative cycle. This region encodes for two regulatory 
proteins, E1 and E2 that control replication and transcription and three oncogenes, 
E5, E6 and E7 that control the transformation process(26, 27). 
 E1 represents the most conservative structure between different types of 
papillomavirus since it is essential for viral replication(27). E1 has binding functions 
for site-specific DNA sequences and shows helicase activity dependent of ATP 
required in the viral DNA replication(26). 
E2 encodes for a protein that will provide an intragenomic regulation of viral gene 
expression by generating dimers at specific binding sites. E2 interacts with E1 by 
stimulating the replication enhancing the binding between the origin of replication 
and E1(26). Deletions in this ORF are highly correlated with the transition of human 
cells into a malignant state. In fact, premalignant lesions do not appear to have E2 
expressed and moreover a mutation in the E2 ORF within the viral LCR has shown 
to contribute for cellular immortalization(26). 
The E4 protein is originated from a single splice sequence between E1 ORF and E4 
ORF that originates the main transcripts in HPV induced lesions(26). In vitro studies 
have shown that E4 interact with the keratin cytoskeleton inducing the collapse of 
this network contributing for cellular indifferentiation(30, 31). 
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E6 and E7 are capable of coding growth-stimulating proteins, this way these genes 
are often found in malignant tumours and are also capable of tissue immortalization 
in cultured cells (26). These proteins are considered the transforming proteins of 
HPV and are responsible for the inactivation of some of the most important cell 
cycle regulators, thus leading to cell proliferation. These events are often observed in 
the majority of HPV-associated cancers and in vitro studies have shown that this 
mechanism is the essential route for HPV-associated carcinogenesis(15, 26, 32). 
E6 is composed by 151 amino acids and two zinc finger structures formed by four 
Cys-X-X-Cys motifs, capable of binding to p53 and promoting its degradation by 
the ubiquitin proteasome pathway(26, 33). This interaction between E6 and p53 
protein causes a genetic instability that prevents cells to enter apoptosis and activate 
repair mechanisms(1, 26). Moreover E7 is able to bind the Retinoblastoma protein 
(pRb) and therefore releases the transcription factor E2F that is required for cell 
proliferation. Hence, the G1 arrest is avoided and cells start to activate the 
proliferation pathway(15, 26, 32). 
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Epstein Barr virus and head and neck cancer 
In 1958, Denis Burkitt theorized that the etiological agent responsible by a cancer 
that was affecting children in several regions of Africa could be a virus(24), later 
this cancer was designated as the Burkitt’s lymphoma (BL) (34) and in 1964 
Epstein, Achong and Barr detected by electron microscopy herpes virus-like 
particles in a cell line obtained from a Burkitt’s lymphoma biopsy and name it as 
Epstein-Barr virus(24). Afterwards, studies revealed that the sera from patients with 
BL had higher antibody titters to EBV than controls, since then, scientific 
community has developed a large number of studies to clarify the role of EBV in the 
aetiology of different diseases(24, 34). The carcinogenic potential of EBV was 
showed in vitro by its ability to transform resting B-cells(24) and by inducing 
lymphomas in cotton-top marmosets and in owl monkeys(34). 
In fact it is known that EBV infection is the cause of infectious mononucleosis (IM) 
and is also associated with several malignancies, such as undifferentiated 
nasopharyngeal carcinoma (UNPC), T-cells lymphoma and immunoblastic 
lymphomas(24, 35). 
 
 Structure and regulation of Epstein Barr Virus 
Epstein Barr virus (EBV) is a gammaherpesvirus from the Lymphocryptovirus 
genus(24) composed by a linear double stranded DNA with 184 kbp(34).  EBV is 
composed by a glycoprotein spiked outer envelope, a protein between the envelope 
and the nucleocapsid, and a nucleocapsid that involves the viral genome in a toroid-
shaped protein core like the other herpesviruses(34). 
After infection, the viral DNA converts into a circular episome with a specific 
number of terminal repeats conserved from the parental genome.  Its viral genome 
presents a series of 0,5kbp of terminal direct repeats and internal repeats sequences, 
which divide the genome into short and long domains that affect genetic 
transcription(34, 36).  
EBV has the ability to produce over 85 proteins, however only some of them are 
well known and have a clear role in infection and transcription(34). From all the 
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EBV proteins the most important are the EBNAs (EBNA-1, EBNA-2, EBNA-3a, 
EBNA-3b, EBNA-3C, EBNA-LP) and the LMPs (LMP-1, LMP2-A and LMP-2B) 
that are important for cellular control and transcription(34, 36). There are mainly 
two EBV subtypes that usually infect humans, the EBV-1 and the EBV-2, which 
differ in the genetic organization of the nuclear antigen (EBNA-2, EBNA-3a, 
EBNA-3b and EBNA-3c)(34, 35).  
Infection by EBV occur mainly in childhood(24), usually transmitted by saliva from 
host to host(34). This infection is not fully understood but primarily begins when the 
oropharyngeal epithelium cells are infected and occur virus replication, due to the 
proximity with the oropharyngeal epithelium the B-lymphocytes will be infected and 
will present a latent state(34). 
An in vitro model of EBV infection and transformation in lymphoblastic cell lines 
showed high expression of some B-cell activation markers revealing that these cells 
were activated by antigenic or mitogenic simulation(24). In fact studies suggest that 
EBV-induced immortalization can be caused by activation of cellular pathways of 
the B-cells proliferation(24, 34, 36). 
 
Viral proteins in Epstein Barr virus 
EBV encodes for a series of latent genes essentials for cells immortalization and 
with different functions like replication, maintenance, transcription or 
signalization(34). 
EBNA-1 has a fundamental role in the maintenance of latent infection, this gene is 
responsible for replication of EBV genome and segregation of viral episomes during 
the mitosis and is constituted by DNA sequence specified in binding the 
phosphoprotein in the origin plasmid replication(34). 
EBNA-2 is responsible for the distinction between EBV-1 and EBV-2 types. This 
transcription factor is necessary for cell immortalization and is one of the first to be 
detected after EBV infection(34). 
EBNA-3 is encoded by three genes that connect to the viral genome and form the 
different types of EBNA-3, the EBNA-3A, the EBNA-3B and the EBNA-3C, all of 
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the three genes are transcriptional regulators but only EBNA-3A and EBNA-3C are 
essential for B-cells transformation and EBV immortalization. Despite the function 
of EBNA-3B is not well known its known that this gene interacts with CBF1 like 
EBNA-3C. EBNA-3C also increases the production of LMP1 and overtakes the pRb 
checkpoints in the cell cycle(34).  
EBNA-LP is also one of the first viral proteins to be produced after EBV infection. 
This gene is composed mainly by RNA splicing sequences where its ORF is 
constituted by two exons, the Y1 and the Y2. EBNA-LP contributes to 
immortalization and also interacts with transcriptional factors and inactivates p53 
and pRb(34). 
LMP-1 act as constitutively active receptor (CD40) and mimics this signal by 
association with the tumour receptor associated factors. This protein can recruit any 
gene and inhibit apoptosis by increasing the levels of Bcl-2 and a-20, this way it is 
responsible by the signalization and the immortalization of the cell(34). 
LMP-2 encodes for LMP-2A And LMP-2B, these proteins are involved in the 
beginning of the latent state of EBV and may be associated with nasopharyngeal 
carcinomas and Hodgkin’s disease but this relation with the oncogene of these 
diseases is yet unknown(34). 
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4. PROTEOMICS AND HEAD AND NECK CARNCERS 
Since Marc Wilkins introduced the word proteome in 1995 great advances have been 
made in the fields of proteomics(37).  
Proteomics can be defined by the identification and detection of proteins based on 
the study of structure, concentration, function, regulation and dynamic interactions 
of proteins (38), these complex information’s can reveal different post-translational 
modifications (PTMs), proteolitic clivages and alternative splicing that can be later 
related with different types of diseases (39).  
With this advances it become important to map all of the proteins, with that purpose 
it was born the Human Proteome Project (HPP) launched by the Human Proteome 
Organization (HUPO) (40, 41). This project was originated with the aim to map the 
proteins functional network in different times and conditions in a particular 
organism, tissue or cell providing this way new information and tools for a better 
understanding in health and disease control (41).  
The integration of new research instruments more advanced and sensitive than 2D 
electrophoresis such has Mass Spectrometry (MS) techniques and bioinformatics 
allowed researchers to identify more than 4000 proteins in a particular shotgun run 
(42) and generate different databases from different organisms(43-45). 
Peptides and proteins can be divided in different platforms in which they are 
characterized and classified according to qualitative and quantitative point of view 
(46, 47). 
In a qualitative platform analysis the all set of peptides, proteins and PTMs present 
in a sample are defined despite the different proteins concentration distribution, this 
approach has disadvantages, for instance in the case of plasma only after the 
depletion of the most abundant proteins the low ones will be revealed (48).  
The need to complete this platform with quantitative information was confirmed 
when researchers found out that the concentration of some proteins or some PTMs 
could be associated with specific diseases and these ones could be eligible as new 
biomarkers (46). Quantitatively this platform can be divided in relative and absolute 
quantification. In a relative quantification it is possible to compare the differences 
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between a healthy versus a pathological proteome subject by statistical approaches 
analysing increases or decreases in protein levels (46). Recent studies also 
demonstrate that increased or unique levels of specific proteins may be associated 
with pathological disorders and many viral diseases(49-51). 
Proteomics technology have also been used as a screening tool due to its sensitivity 
and specificity, to diagnose and early detect cancer disease, cancer-specific 
alterations in protein abundance or in PTMs like glycosylation or phosphorylation 
that can be developed as early disease biomarkers(52, 53).  
An ideal cancer biomarker can be a protein, RNA, cytokine, carbohydrate or 
chemokine and should have a high analytical sensitivity and specificity that allow an 
easy and reliable analysis (25, 54).  
Several proteins can be differently expressed or secreted comparing healthy controls 
with patients with cancer providing different protein expression signatures that allow 
researchers to identify new biomarkers (55, 56). When a new protein biomarker is 
identified new bioinformatics techniques like protein chips with specific modified 
chromatographic surfaces and a specific protein pattern acquired by the MS 
technique can be developed as a diagnostic procedures when combined with a 
precise algorithm that allow to classify the sample as unclassifiable, healthy or 
disease affected patient (57).  
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5. SALIVARY PROTEOMICS 
Numerous studies in genomic and proteomic fields in the last 10 years lead to the 
discover of several biomarkers that help the clinicians to predict and evaluate the 
prognosis of a cancer, this way clinicians can evaluate the predisposition of a patient 
to a specific cancer and screen it in a early phase in a manner to improve the clinical 
outcome(58).  
Recent studies combining the new MS proteomic techniques with quantitative and 
qualitative proteomics approaches have provided the capability to identify large 
number of proteins from different biological fluids samples such as plasma/serum, 
urine, cerebrospinal fluid, bronchoalveolar lavage fluid, synovial fluid, nipple 
aspirate fluid, tear fluid, amniotic fluid and saliva (58, 59) 
Saliva has proven to be an appealing sample in proteomic research and clinical 
applications due to its salivary proteome that could provide a diagnosis for several 
diseases trough MS analysis (60-62).  
The profiling of these proteins with high sensitivity and specificity could indicate 
different hereditary diseases and autoimmune diseases like Sjögren's syndrome, 
systemic sclerosis and diabetes, several malignancies and cancers and several oral 
diseases like periodontitis and dental caries allowing a better diagnosis and treatment 
by the clinicians(55, 63-68). 
Whereas approximately 20% of these salivary proteins can also be found in human 
plasma with similar functions and disease-linkage, recent studies demonstrate that 
increased or unique levels of specific proteins may be associated with pathological 
disorders such as immunodeficiency virus or systematic diseases(49, 50, 55, 69). 
In fact, the high sensitivity and specificity of these methods could indicate different 
stages of several diseases or give information about body conditions by measuring 
systemic levels of drugs in case of illicit drug use or measure the immune response 
to viral or bacterial infections allowing the clinicians to provide a better diagnosis 
and treatment (69-71).  
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Saliva analysis can be divided in the analysis of the whole saliva for disease 
diagnosis or in the analysis of gland-specific saliva to analyse a specific pathology in 
a specific major gland(69). 
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5.1 Composition of Saliva 
Saliva is a biofluid that not only serves to lubricate and protect the oral cavity or to 
help in the digestion but has also functions that will maintain the mouth 
homeostasis(72, 73). Besides that, this biofluid also offer distinctive advantages in 
diseases diagnosis when compared to other biologic fluids, the fact of this fluid 
doesn’t require special collection equipment’s or the fact of its low cost and non-
invasiveness makes of this fluid a valuable asset in the diagnosis of diseases 
specially in patients like children or older adults(74).  
Human Saliva is produced in the oral cavity by three major salivary glands; parotid, 
sublingual and submandibular and several minor glands. Specific collection from 
each individual gland could provide information about gland-specific pathologies 
like infections, however, after the production of saliva from submandibular glands 
and sublingual glands the saliva from both glands enters the oral cavity trough the 
Wharton’s duct making the separate collection from this glands a difficult 
process(75) – Figure 6 . 
 
   
Figure 6 - Salivary glands anatomy 
 
Whole saliva is a mixture from the secretions of the different glands and from non-
salivary constituents such as expectorated bronchial and nasal secretions, serum and 
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blood derivatives, cellular components and epithelial cells, gingival crevicular fluid 
which is composed by bacterial and viral products and food debris (76-78).  
Water, several electrolytes (sodium, calcium, potassium, magnesium, phosphates 
and bicarbonate), mucins, immunoglobulins, nitrogenous products, enzymes, nucleic 
acids, lipids, peptides and proteins mainly compose this biofluid(79, 80). All of 
these components have specific functions: bicarbonates and phosphates are 
important in the modulation of the pH in order to maintain the buffering capacity of 
saliva; mucins and macromolecule proteins contributes to the homeostasis 
maintenance of the dental plaque metabolism; phosphate calcium and proteins work 
in the modulation of demineralization and remineralisation processes and 
immunoglobulins, enzymes and proteins have antibacterial action (80-83).  
Peptides and proteins present in saliva are multifunctional (81) and can be classified 
in five main groups; histatins, cystatins, proline-rich proteins (PRP), defensins and 
statherins – Table IV. (84) The proline-rich proteins can be subdivided in basics 
proline-rich proteins (bPRP), acidic proline-rich proteins (aPRP) and glycosylated 
proline rich-proteins (gPRP)(85). 
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Table IV - Salivary proteins - Origin and functions of most abundant salivary proteins 
(adapted from (107)) 
Protein Family Functions Origin 
Alpha Amylases Antibacterial, digestion, tissue coating Parotid; Submaxillary; 
Sublingual 
Acidic PRPs Lubrication, mineralization, tissue coating Parotid; Submaxillary; 
Sublingual 
Basic PRPs Binding of tannins, tissue coating Parotid 
Basic Glycosylated 
PRPs 
Antiviral, lubrication Parotid 
Carbonic anhydrase 
VI 
Buffering, taste Parotid; Submaxillary 
Cystatins Antibacterial, antiviral, mineralization, 
tissue coating 
Parotid; Submaxillary; 
Sublingual 
Histatins Antifungal, antibacterial, mineralization, 
wound-healing 
Parotid; Submaxillary; 
Sublingual 
Lactoferrin Antibacterial, antifungal, antiviral, innate 
immune response 
All salivary glands 
Lysozyme Antibacterial Parotid; Submaxillary 
Mucins Antibacterial, antiviral, digestion, 
lubrication, tissue coating 
All salivary glands 
Peroxidases Antibacterial Parotid; Submaxillary 
Statherins Inhibition crystal form, lubrication, 
mineralization, tissue coating 
Parotid; Submaxillary; 
Sublingual 
Albumin Carrier protein Gingival crevicular fluid 
Alpha Defensins Antibacterial, antifungal Gingival crevicular fluid 
S100 A proteins Different functions Various 
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Beta Thymosins Different functions Gingival crevicular fluid 
 
 
Since its composed by a large spectrum of proteins, recent proteomic technologies 
have been use to analyse and identify the salivary proteome quantitatively and 
qualitatively(69). 
In the past years researchers have been catalogue the human proteins in the whole 
saliva using several MS platforms in order to understand the peptide/protein 
composition of this fluid(86). 2100 intact proteins from the aqueous supernatant of 
whole saliva were identified in one study allowing the researchers to discover that 
exist a significant overlap of proteins when compared to human serum proteome(86, 
87). The insoluble part of the saliva also contains proteins; these proteins are mainly 
from exosomes and membrane vesicles secreted from cells presents in other body 
fluids(88). 
With the development of MS databases it became important to map the structures 
and functions of the primary sequences of the proteins highly regulated by post-
translation modifications (PTMs), some examples of this modifications are 
glycosylated or phosphorylated proteins and they allow to discover news hints in 
protein dysfunction when submitted to risk factors(89). 
Besides the intact proteins and the PTMs whole saliva also have present low 
molecular weight proteins – peptides – with many biological functions. The salivary 
peptidome can also be used as diagnostic biomarker, is moderately stable to 
degradation and will complete the information collected from the intact proteins and 
the PTMs(89).  
Several studies also indicate noticeable differences in the salivary proteome when 
comparing samples from children with samples from adults (90, 91) this way in our 
study we pretend to choose controls with the same year ranges than our patients. 
 
 
5.2 Salivary proteome and Head and Neck Cancer  
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Clinicians are constantly searching for clinical applications that could monitoring a 
disease status, its the beginning, its progressions and its treatment outcome, for this 
propose they use a series of pre-requisites such as a specific biomarker for the 
disease in study, a technique for the biomarker study that does not involve an 
invasive approach and the use of technologies that allow to distinguish the different 
biomarkers(69).  
As seen before saliva is a body fluid present in the oral cavity mainly composed by 
water (99,5%), proteins (0,3%) and inorganic substances (0,2%)(92) and its 
relationship with plasma levels makes of this easy to obtained body fluid with non-
invasive nature and low cost processing an attractive diagnostic tool (86, 92). 
Despite the amount and composition of this body fluid depend patience health 
status(84) and according to many factors such as age, gender, blood type, size of the 
salivary glands; scientists are searching biomarkers in human saliva proteome for 
early detection of oral cancers (86, 93-95). 
The primary reason for the high mortality rate in oral cancers is mainly the delayed 
detection once most of the patients present symptoms in a late stage provoking a 
higher recurrence rate after the first treatment(86). This fact supports the need for 
biomarkers with high sensitivity, specificity, and functionality in the detection of 
early stage head and neck cancers(69, 86). 
Detection of differentially expressed proteins trough a mass spectrometry method 
revealed cytokeratin 4 and 13, zinc finger proteins, P53 pathway proteins, annexin 
A1 and beta and gamma actins as potential biomarkers for HNSCC and revealed 
also high levels of salivary transferrin in oral squamous cell carcinomas (OSCC) 
patients which proved to be highly specific and sensitive in the detection of 
OSCC(69). Another MS study validated by immunoassays also found that the 
combination of increased levels of S100A9, profiling, CD59, catalase and MBP2 
could detect OSCC with 90% of sensitivity and 83% of specificity (86)  
Different techniques as Matrix-assisted laser desorption/ionization mass 
spectrometry (MALDI-MS), Quantitative real time (RT-PCR), High performance 
liquid chromatography (HPLC) and DNA and RNA microarrays provide also 
potential biomarkers in the early detection of OSCC such as; albumin, endothelin-1, 
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Immunoglobulin heavy chain constant region gamma, transthyretin and also 
transferrin(96). 
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6. Viral Proteomics in Head and Neck cancers  
Saliva contains a vast number of proteins that researchers believe to be involved in 
extensive variety of biological functions, metabolites as well as microRNA and 
mRNA transcripts (97-99). 
The increasing of sensitivity in the genomic and metabolomics improved different 
methods of virus diagnostic in saliva samples allowing the association of EBV to 
nasopharyngeal carcinoma which according to literature presents higher levels of 
EBV DNA in stages 3 and 4 than in stages 1 and 2 (100). 
Notwithstanding peptides and proteins are vulnerable to degradation since they 
generally have short half-lives, protein stabilization methods allowed MS (101, 102) 
analysis and recent studies demonstrate that increased or unique concentration levels 
of specific proteins may be associated with pathological disorders, mainly viral 
diseases(49-51).   
Moreover this sample may be even more important to evaluate and following 
patients with viral infections of the oral cavity. In fact, many studies have been 
designed to identify tumour-associated markers in saliva(69, 103, 104). Despite the 
viral detection in samples not always allow a good correlation with clinic once a 
huge number of viruses is in the latent state in several types of tissues. This way the 
detection of viral markers can be a better approach for the identification of risk 
units(51). Since different types of peptides and proteins compose saliva we believe 
that is possible to identify viral peptides/proteins in this type of sample. 
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7. PROTEOMIC AND PEPTIDOMIC FINGERPRINT AS A POSSIBLE 
DIAGNOSE TOOL FOR HEAD AND NECK CANCERS 
 
When saliva enters the oral cavity, protein salivary secretion will be vulnerable to a 
variety of biochemical and physiological processes promoted by a series of enzymes 
from the individual and from bacteria. This process will induce several post-
translational modifications (105).  
After the transcription and translation of the genes involved in the protein 
biosynthesis in the glands, several post-translational events like protein 
phosphorylation, glycosylation and proteolysis (exo and endo) will take place and 
the salivary proteins that enters in the oral environment will be formed with similar 
structural differences, originating different protein families (105, 106). Subsequently 
saliva enters the oral cavity and continues to suffer protein modifications that will 
lead to protein-protein complex formation, partial deglycosylation and a widespread 
of exogenous proteolitic cleavages until swallowing (105). 
As we have seen before the major salivary proteins are secreted from different 
glands and will suffer different types of post-translational modifications. Several 
studies included in Castagnola review allowed the scientific community to be better 
elucidated about novel functions for different families of specific peptides and 
proteins(107). In table V is showed the most relevant post-translational 
modifications of salivary proteins. 
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Table V - Common Post translational modifications in Saliva proteins (adapted from 107) 
Precursor Protein Matures 
proteins 
Post-translational 
modifications 
Salivary acidic proline-rich 
phosphoprotein 1 
Db-s, Pa, PIF-s, 
Pa 2-mer, 
Db-f, PIF-f, P-C 
peptide 
Disulphide, further 
proteolytic 
cleavages, N-terminal 
pyro-Glu, 
phosphorylation, 
transglutamination 
Salivary acidic proline-rich 
phosphoprotein 2 
PRP-1, PRP-2, 
PRP-3, 
PRP-4, P-C 
peptide 
Further proteolytic 
cleavages, 
N-terminal pyro-Glu, 
phosphorylation, 
transglutamination 
Basic salivary proline-rich 
protein 1 
II-2, P-E, IB-6 
Further proteolytic 
cleavages, 
N-terminal pyro-Glu, N- 
and 
O-glycosylation, 
phosphorylation, 
transglutamination 
Basic salivary proline-rich 
protein 2 
IB-1, IB-7, IB-8a 
(Con1_/+), 
P-F, P-J, P-H 
Further proteolytic 
cleavages, 
N-glycosylation, N-
terminal 
pyro-Glu, 
phosphorylation, 
transglutamination 
Basic salivary proline-rich 
protein 3 
Proline-rich 
protein Gl 1-8 
Disulphide (Gl 8), N- 
and 
O-glycosylation, N-
terminal 
pyro-Glu, 
phosphorylation 
Basic salivary proline-rich 
protein 4 
Salivary proline-
rich 
protein Po, 
protein N1, P-D, 
N-glycosylation 
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II-1, 
CD-IIg 
Hst 1 nonP Hst 1, Hst 2 
Further proteolytic 
cleavages, 
phosphorylation, 
sulfation 
Hst 3 
Hst 3, Hst 5, Hst 
6 
Further proteolytic 
cleavages 
Mucin-5B precursor Mucin-5B 
N- and O-glycosylation, 
disulfide, 
phosphorylation 
Mucin-19 precursor Mucin-19 Disulphide 
Mucin-7 precursor Mucin-7 (MG2) N- and O-glycosylation 
Cyst SN precursor Cyst SN Disulphide, sulfoxide 
Cyst SA precursor Cyst SA Disulphide 
Cyst C precursor Cyst C O-glycosylation 
Cyst S precursor Cyst S 
Disulphide, 
phosphorylation 
Cyst D precursor Cyst D 
Disulphide, truncated 
forms 
Statherin precursor 
Statherin, 
statherin SV2 
Phosphorylation, 
proteolytic 
cleavages, 
transglutamination 
Proline-rich peptide P-B 
Precursor 
Proline-rich 
peptide P-B 
N-terminal pyro-Glu, 
proteolytic cleavages 
a-amylase 1 precursor a-amylase 1 
Disulphide, N-
glycosylation, 
N-terminal pyro-Glu, 
phosphorylation, 
proteolytic 
cleavages 
Neutrophil Def 1 precursor a-Def 1 and 2 
Disulphide, 
phosphorylation 
Neutrophil Def 3 precursor a-Def 3 and 2 
Disulphide, 
phosphorylation 
Neutrophil Def 4 precursor a-Def 4 Disulphide 
Tb4 precursor Tb4 
Acetylation, 
phosphorylation, 
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proteolytic cleavage, 
sulfoxide, 
transglutamination 
Tb10 precursor Tb10 
Acetylation, 
phosphorylation, 
transglutamination 
Protein S100A7 precursor Protein S100A7 
Acetylation, disulfide 
bond 
Protein S100A9 precursor 
Protein S100A9, 
protein S100A9 
(short type) 
Phosphorylation, 
sulfoxide 
 
Since all of these processes suffers from the singleness of the individual, this 
information can be seen as fingerprint in which it is possible to link specific post-
translational modifications to a specific pathology and determine in which way it 
affects or promotes its development (107). 
Several MS studies with different types of stimulation and validated by molecular 
biology techniques, identified different biomarkers according to different types of 
head and neck cancers (107). 
Pre cancerous and cancerous lesions of oral cavity revealed decreased levels of 
Statherins; oral cancers revealed increased levels of actin, myosin and albumin; 
HNSCC revealed increased levels of a-1-B-glycoprotein, complement factor B, a-1-
acid-glycoprotein-2, fibronectin1, kininogen, Ig heavy chain C region gamma 2, 
transferrin, S100A9, fibrin b and cofilin 1; OSCC revealed increased levels of alpha-
Def-1, M2BP, S100A9, protectin, catalase, profiling, Cyst SN and Transferrin (107). 
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8. PROTEOLITIC ACTIVITY IN HEAD AND NECK CANCERS 
 
As we have seen before one of the constituents of human whole saliva are enzymes, 
some of these were already identified and they include catalase, amylase, carbonic 
anhydrase and proteases(108, 109). Alterations made by proteases results in smaller 
peptides and low-molecular-weight proteins (a significant fraction on the salivary 
proteome) unique for each individual(110).  
Subsequently, the identification and characterization of the salivary proteases that 
modify structures and functions of salivary proteins involved in oral diseases (109) 
are a fundamental step to understand the oral microenvironment in proteolitic 
associated diseases or in health individuals(110). Furthermore it can also act as tool 
in clinical diagnosis and prognosis(110).  
In spite of the fact that until today over 200 salivary peptides were identified, 
proteolitic cleavage events are not completely understood(109).  However it is 
known that the majority of the peptides from the proteolytic fragmentation belong to 
PRPs, histatins and statherins(109).  
With the view to understand the peptide formation trough proteolitic activity in 
saliva, several studies have been adopting different approaches and been relating 
small peptides to Cathepsin D, to trypsin, chymotrypsin or elastase activity (109). 
Cysteine peptidases like Cathepsins B, C, H and L, with strong anti bacterial and 
anti viral properties are inhibit by cystatins isoforms (S, C, D, SA, SN)(84).  
Most of the peptides fragments found in saliva derive from PRPs, statherins and 
histatins there are extremely proteolyzed in oral cavity by proteases from epithelial 
cells, leukocytes from the gingival exudate, from the dental plaque and from several 
microorganisms(84). 
Proteolytic activities may modulate functional activities or affect a disease state; this 
way the rate of proteolysis in saliva and in dental plaque could indicate dental caries 
vulnerability and periodontal disease(84).  
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9. OBJECTIVES 
The present work can be described in two main goals: 
First we aim to identify viral peptides/proteins in saliva prevenient from head and 
neck cancer patients and correlate the different peptides/proteins obtained from the 
saliva’s from the patients with the presence or absence of EBV and HPV. 
Second we aim to identify a peptidomic fingerprint of the proteome and the 
degradome of saliva’s from patients with HNSCC. 
Both approaches have the main objective to correlate these factors with different 
types of head and neck cancers in order to create a new diagnostic tool.  
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10. METHODOLOGY 
10.1 Type of study 
This work was preformed in the University of Aveiro and at the Molecular 
Oncology Group of the Portuguese Institute of Oncology of Oporto (IPO Porto FG 
EPE) with the collaboration of Virology Service from IPO Porto using the technical 
resources existent in the laboratories of these institutes. 
This study was developed as a prospective case-control study with consecutive 
patients attended at IPO Porto FG EPE during the period of February to May of 
2013 selected according with the criteria previously defined: 
Inclusion Criteria: 
- Patients with diagnosis of squamous cell carcinomas in the oral cavity and 
nasopharynx 
- Histological confirmation of diagnosis  
- Patients have to accept to provide samples of tissue, blood and saliva 
Exclusion Criteria: 
- Prior head and neck cancer 
- Prior treatments of radiotherapy and/or chemotherapy 
- Presence of blood in the saliva sample 
- Patients that does not accept to participate in this study 
Control Group 
The control group was constituted by healthy individuals from Blood Donor 
Database at IPO Porto FG EPE with matched age and gender without history of 
cancer. 
Ethical questions 
This study did not interfered with the routine procedures decided by clinicians. 
Clinicopathological data was collected from individual clinical records and inserted 
on a database with unique codification. All procedures were submitted to approval 
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of the IPO Porto FG EPE Ethical Committee and all samples were obtained with the 
informed consent of the participants according to the Declaration of Helsinki.  
 
11. MATERIAL AND METHODS 
 
11.1  Saliva Samples 
Saliva samples should provide us a wide range of comparison between the healthy 
subjects that should not exhibit any evidence of oral inflammations or pathologies 
(control group) and between the subjects of the disease in study (Study group)(17, 
49). 
These samples were collected according to standardized techniques in the 
Portuguese Institute of Oncology and will be kept refrigerated until their processing. 
Furthermore processed saliva was analysed in University of Aveiro with MS/MS 
techniques described further.  
 
11.2 Patients and control groups 
Samples from 82 patients with pathologies from oral cavity, pharynx and larynx 
areas were collected. From the samples collected 11 patients were excluded because 
they didn’t fulfil the pathology inclusion criteria. 27 patients were excluded because 
they didn’t have sufficient saliva sample for analysis. 
Subjects included in the present study included 44 patients with head and neck 
carcinomas (confirmed histologically) with range ages between 34 and 72 divided in 
3 groups: 24 in the Larynx group, which include Laryngeal and Vocal chords SCCs; 
16 in the Pharynx + Oral Cavity group which include Floor of the mouth, Uvula and 
soft palate, tonsils, tongue, pharynx, pharyngolarynx, oropharynx and hypopharynx 
SCCs and 4 in the Nasopharynx + Nostrils group composed by nasopharynx and 
nostrils carcinomas.  
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The patients were followed up at Otorhinolaryngology Service at Portuguese 
Institute of Oncology Porto FG EPE and patients with prior head and neck cancers, 
prior treatments of surgery, radiotherapy and/or chemotherapy or samples with 
presence of blood in the saliva were excluded.  
The HNSCC patients were compared with a control group composed by 10 healthy 
individuals without history of cancer and range ages between 47 and 72, collected in 
the North region of Portugal after a medical screening with internal physicians of 
Portuguese League Against Cancer. The clinical characteristics of enrolled subjects 
are summarized in Table VI. 
 
Table VI - Clinical characterization of the study subjects 
Patient Sex Age Diagnosis Group Tobacco 
packages 
per year 
Alcohol 
Grams 
per day 
Control 
Group 
      
C1 
C2 
C3 
C4 
C5 
C6 
C7 
C8 
C9 
C10 
M 
F 
M 
M 
M 
M 
M 
F 
M 
M 
59 
64 
47 
60 
64 
58 
57 
72 
59 
51 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
  
Study 
group 
      
1 M 67 Vocal Chords SCC Larynx 13 36 
2 F 72 Vocal Chords SCC Larynx No  No 
3 M 44 Vocal Chords SCC Larynx 53 26 
4 M 59 Vocal Chords SCC Larynx 40 52 
5 M 55 Laryngeal SCC Larynx 15 * 
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6 M 57 Laryngeal SCC Larynx 74 * 
7 M 67 Laryngeal SCC Larynx 54 72 
8 M 63 Laryngeal SCC Larynx No 144 
9 M 47 Laryngeal SCC Larynx 32 36 
10 M 56 Laryngeal SCC Larynx 60 108 
11 M 60 Laryngeal SCC Larynx 40 72 
12 M 37 Laryngeal SCC Larynx 39 72 
13 M 55 Laryngeal SCC Larynx 44 72 
14 M 64 Laryngeal SCC Larynx No 72 
15 M 59 Laryngeal SCC Larynx 88 72 
16 M 67 Laryngeal SCC Larynx - - 
17 M 46 Laryngeal SCC Larynx 25 72 
18 M 34 Laryngeal SCC Larynx 15 102 
19 M 53 Laryngeal SCC Larynx 43,75 120 
20 M 50 Laryngeal SCC Larynx 30 72 
21 M 55 Laryngeal SCC Larynx 30 72 
22 M 72 Laryngeal SCC Larynx 200 72 
23 M 48 Laryngeal SCC Larynx 74 72 
24 M 53 Laryngeal SCC Larynx 32 26 
25 F 87 Tongue SCC Pharynx+ Oral 
Cavity 
15 36 
26 M 49 Oropharyngeal 
SCC 
Pharynx+ Oral 
Cavity 
30 No 
27 M 67 Oropharyngeal 
SCC 
Pharynx+ Oral 
Cavity 
40 39 
28 M 58 Oropharyngeal 
SCC 
Pharynx+ Oral 
Cavity 
96 72 
29 M 57 Oropharyngeal 
SCC 
Pharynx+ Oral 
Cavity 
20 72 
30 M 56 Mouth floor SCC Pharynx+ Oral 
Cavity 
61,5 * 
31 M 39 Mouth floor SCC Pharynx+ Oral 
Cavity 
2,45 26 
32 M 59 Uvula and Soft 
palate SCC 
Pharynx+ Oral 
Cavity 
44 72 
33 M 52 Tonsil SCC Pharynx+ Oral 
Cavity 
45 181,75 
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34 M 49 Tonsil SCC Pharynx+ Oral 
Cavity 
35 300 
35 M 54 Tonsil SCC Pharynx+ Oral 
Cavity 
40 48 
36 M 50 Pharyngeal SCC Pharynx+ Oral 
Cavity 
45 117 
37 M 51 Pharyngolaryngeal 
SCC 
Pharynx+ Oral 
Cavity 
39 * 
38 M 63 Pharyngolaryngeal 
SCC 
Pharynx+ Oral 
Cavity 
80 72 
39 M 48 Hypopharyngeal 
SCC 
Pharynx+ Oral 
Cavity 
- - 
40 M 57 Hypopharyngeal 
SCC 
Pharynx+ Oral 
Cavity 
40 ** 
41 M 46 Nostrils Nasopharynx 
+ Nostrils 
No ** 
42 M 52 Nostrils Nasopharynx 
+ Nostrils 
30 36 
43 M 63 Nostrils Nasopharynx 
+ Nostrils 
No ** 
44 M 34 Nasopharynx Nasopharynx 
+ Nostrils 
No ** 
(* former consumer; **sporadically consumer) 
 
 The present study was approved by the IPO Porto FG EPE Ethical Committee and 
all of the subjects included had been informed of the nature of the current research 
and had given their written informed consent according to Declaration of Helsinki.  
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11.3 Sample collection: 
 
Saliva collection was performed to all of the study individuals after two hours of the 
patient last meal without parotid stimulation to a sterilized glass. This was followed 
by the addition of a 250μL 6M Urea solution per 1mL of saliva, divided 200μL 
factions and frozen at -80ºC until further analysis. 
 
11.4 Sample preparation: 
Fractionated saliva samples were submitted to centrifugation at 12000g for 10 min at 
4ºC to remove possible food remains, cell debris and bacteria. Supernatant was 
collected adding 60 μL of 20% acetonitrile and resubmitted to centrifugation at 
12000g for 10 min at 4ºC in case of visual precipitate after 5 min at room 
temperature. Spin filters (50 kDa cut-off) were conditioned with the supernatant and 
submitted to a 12000g centrifugation for 20 min at 4ºC and then 40μL of ammonia 
hydrogenocarbonate 50mM was added to the spin filters resubmitting it to a 12000g 
centrifugation for 20 min at 4ºC. Filtrates were then separated in one fraction of 
100μL and two fractions of 50μL and the 50μL fractions posteriorly submitted to 
Speed Vac. All of the filtrates were stored at -80ºC for posterior peptide separation 
and identification. 
 
11.5 Nano HPLC peptide separation: 
Dried extracted peptides were resuspended in 5μL of a 0.3; 49.7; 50 trifluoracetic 
acid/water/acetonitrile (v:v:v) solution and submitted to ultrasounds 3 min. Samples 
were then spin centrifuged until 10000g and a 25μL solution of trifluoracetic acid 
0.1% was added  to the mix sample submitting it again to 3 min of ultrasounds and 
spin centrifugation. 
Separation was preformed with 10μL of each sample in C18 column Pepmap (Dionex) 
in a Nano-HPLC 3000 Ultimate (Dionex/LC Packings, Sunnyvale, CA) and the 
fractions collected with Probot (Dionex/LC Packings, Sunnyvale, CA) directly by a 
laser desorption-ionization (MALDI). 
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MS/MS spectra were obtained in a 4800 MALDI-TOF/TOF Analyser (Applied 
Biosystems, Foster City, CA) and processed with Mascot software (v.2.1.0.4) for 
peptide/protein identification. Searches were made against Swissprot protein 
database with two different search approaches:  
The first search approach was in Virus database with none enzyme selection, 40 ppm 
MS tolerance for precursor ions, 0.5 Da tolerance for fragment ions and with +1 
peptide charge. Positive identification was considered for default significance 
threshold p<0.05 and individual ion scores above 44. 
To estimate the false discovery rate (FDR), a database of decoy reverse database was 
created for all SwissProt resulting in 5 % FDR (false positives/ peptides (false 
positives + Total peptides)) × 100, only the peptides obtained from search FDR were 
considered for analysis. 
Furthermore, all of the identified peptides were manually submitted to a standard 
protein blast at http://blast.st-va.ncbi.nlm.nih.gov/Blast.cgi in a Non-redundant 
protein sequences (nr) database with a protein-protein blast (blastp) algorithm with 
expect threshold of 20000 and with PAM 30 matrix and then validated. 
The second search approach was in Homo sapiens database with none enzyme 
selection, 40 ppm MS tolerance for precursor ions, 0.5 Da tolerance for fragment 
ions, +1 peptide charge and with Phospho (ST), Phospho (Y), HexNac(N) and Glu-> 
pyro Glu (N-term-E) as variable modifications. 
Identified peptides were discarded if the unique peptide score were below the 
minimal Mascot score comparing with the sample score. Modified protein 
abundance indexes (emPAI) were retrieved for each of the peptide for further 
quantifications and measurements. 
Peptides found in each sample were associated with the proteins that they belong 
and a list of peptides and proteins was created according with the different groups 
established before. Protein-protein interaction analysis was performed with 
Cytoscape v3.1.1 and with ClueGo v2.1.3 (Biological process database 22-09-2014) 
and CluePedia. 
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Terminal-N and Terminal-C residues of each studied individual were analysed by 
type of cancer and type of group and the most common amino acids cleaved residues 
were submitted to Merops peptidase database (http://merops.sanger.ac.uk/cgi-
bin/specsearch.pl) and tables of possible peptidases by amino acid residues were 
created. 
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12. RESULTS 
12.1 First search approach: Virus: 
To identify viral peptide/proteins presents in saliva we preformed the first search 
approach as described before to all of the subjects in Table VI. We were able to find 
29 different viral peptides from 27 different virus species as listed in Table IX.  
From the 54 studied individuals only 18 cancer patients presented viral peptides 
associated with different types of virus as listed in the Table IX. None of the control 
subjects presented any viral peptide/ proteins. 
Results from this method were compared with a previous study from the same 
research group with the same patients in which was tested the prevalence of HPV, 
and EBV in saliva and tissue samples of head and neck cancer patients.  
68 patients (65 male and 3 female) with age ranges between 34 and 87 were 
included in the study. HPV was detected in DNA saliva and tissues by restrict 
fragment length polymorphism (RFLP) using MY09/11 and confirmed by GP5+/6+ 
primers protocols. Detection of EBV was performed using an in house real time-
PCR protocol. The table VII and VIII shows the results of that study. 
 
Table VII - HPV results from the same studied individuals by standardized methods from a 
previous study from the same research group published in the University of Aveiro 
Repository by Esteves and all with the title “Infeção por HPV e EBV em tumores de cabeça e 
pescoço “ 
 
 
 
 
 
 
 
HPV Saliva (n=66) Biopsies (n=42) 
 Positive Negative Positive Negative 
Male 1 62 2 38 
Female 1 2 1 1 
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Table VIII - EBV results from the same sudied individuals by RT-PCR from a previous study 
from the same research group published in the University of Aveiro Repository by Esteves 
and all with the title “Infeção por HPV e EBV em tumores de cabeça e pescoço “ 
 
 
 
 
 
 
 
 
  
EBV Saliva (n=66) Biopsies (n=42) 
 Positive Negative Positive Negative 
Male 46 17 22 18 
Female 3 - - 2 
Table IX - Viral peptides, proteins and virus associated found in the studied subjects. None of the controls exhibit any viral peptides. 
Patient 
Peptides 
Start 
peptide 
End 
Peptide 
Score Protein Species 
4 
AHLEPSQRGKKRKRVDDDAGGSAPAQHVPPPQLDHPGREAI 52 92 152.17 
EBNA3_EBVA
8 
Epstein-Barr virus 
(human herpesvirus 4) 
13 
YDVLPPELWVK 2 12 153.88 YR901_MIMIV 
Acanthamoeba 
polyphaga mimivirus 
17 VMDAADCFRNSADR 574 587 22.60 RDRP_BTV Bluetongue virus 
18 
CGCQDKHHDRHDPCV 49 63 99.45 YR623_MIMIV 
Acanthamoeba 
polyphaga mimivirus 
19 
ENTESYAGPDRTAVVGGGFLTTVDQSS 22 48 152.69 POLG_AEVCA 
Avian 
encephalomyelitis virus 
 PTAAAPRPRPPPPGVGPGGGADPSHPPSRPFRLPPRLALRLRV 96 138 152.69 ICP34_HHV11 Human herpesvirus 1 
 GASLAGKAAKAACSVVDVYAPSFEPYLH 2998 3025 111.35 RPOA_EAVBU Equine arteritis virus 
 
LQHNGCIAWEFDDEKESPGQGSCYFYTNSH 118 147 107.68 EV164_ASFK5 
African swine fever 
virus 
 
PPDNPPPPRRARRSQRHADARGPPP 723 747 91.67 
POLN_RUBVB 
Rubella virus 
POLN_RUBVC 
20 
VPPPPNPSR 212 220 162,25 
PHOSP_MEAS
C Measles Virus 
 V_MEASC 
 PPVNDLKY 880 887 152,09 POLG_DEN4T Dengue virus 
 46 
 POLG_DEN4P 
 POLG_DEN4S 
 POLG_DEN4H 
21 PGAQRAGGPPSTCSPSSPTSWSCCSSSPRRTRGWGPAGGPVRDS 2639 2682 88.78 TEGU_EHV2 Equid herpesvirus 2 
 
CLPTLVDCIRNCISKVLGYTVIAMPEIGDEEETVQM 803 838 50,32 ENV_FIVU8 
Feline 
immunodeficiency virus 
 
PRPAGATGGGGGGVHANGGSVFGHPTGGTSTPAHPPP 
189 225 
47,04 
LT_POVMC 
Murine polyomavirus 22 
194 230 
LT_POVMA 
 LT_POVM3 
23 
PPPPPVPQED 
711 720 
100.85 
UL69_HCMVA Human 
cytomegalovirus 
(Human herpesvirus 5) 
 
709 718 
UL69_HCMV
M 
 
PPPPPIRSPD 648 657 100.85 
POLR_TYMV Turnip yellow mosaic 
virus  POLR_TYMVC 
 
QESECVCVNGSCFTIMTDGPSNG 227 249 133,38 
NRAM_I00A1 
Influenza A virus  NRAM_I80AA 
 NRAM_I83A1 
24 PPVTPAPPTRAP 35 46 97.12 GL_SUHVK Suid herpesvirus 1 
28 PPVTPAPPTRAP 35 46 134.64 GL_SUHVK Suid herpesvirus 1 
 PQGPLPAPPNSKTKSMFKRPGRGSVRSLK 440 468 49.75 ATI2_EHV4 Equid herpesvirus 4 
30 YVGNGTWVHNNTFNVTRYD 39 57 66.55 GH_EHV4 Equid herpesvirus 4 
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31 
PPDQASD 2368 2374 152.06 
POLG_HCVJA 
Hepatitis C virus 
POLG_HCVR6 
32 
PRLPGPNPVSIERKDFEKLKQ 54 74 152.80 MCE_PBCV1 
Paramecium bursaria 
Chlorella virus 1 
 
LLLVVDFVFVIILLLVLTFVVPRLQ 9 33 103.83 MVP2_GLRV3 
Grapevine leafroll-
associated virus 3 
 
QPGADGFELQHPY 221 233 52.45 
POLG_HE71B 
Human enterovirus 71 
POLG_HE71M 
36 PPSPPAPAAAPRPSASSASATSSSAAASPAPAPEPARPPRRKRRS 425 469 128.92 IE18_SUHVF Suid herpesvirus 1 
37 
PGGPYKVGTSGSCPNVTNGNGFFATMAWAVPKNDNNKTA 
131 169 
62.53 
HEMA_INBNA 
Influenza B virus 
HEMA_INBF2 
146 184 
HEMA_INBBE 
HEMA_INBVK 
40 
PPPPPVPQED 
711 720 
70,56 
UL69_HCMVA Human 
cytomegalovirus 
(Human herpesvirus 5) 
 
709 718 
UL69_HCMV
M 
 
PPPPPIRSPD 648 657 70,56 
POLR_TYMV Turnip yellow mosaic 
virus  POLR_TYMVC 
41 PGAPGVKGFGFLNGDNTWLGRTISPRSRSGFEMLKIPNAGTD 344 385 31.44 NRAM_I85A3 Influenza A virus 
43 
TLLGNKTFRTSFVDGAVLETNGPERHN 565 591 152.28 
POLN_HEVBU 
Hepatitis E virus 
 POLN_HEVCH 
 48 
 POLN_HEVHY 
 POLN_HEVPA 
 PVNLLGRSVLQSIVTKFTLAAHTKQIQPLPV 517 547 152.28 POL_JEMBR Jembrana disease virus 
 LISDIGLEEDNGAID 344 358 152.28 V120_GAHVM Gallid herpesvirus 2 
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12.2 Second search approach: Homo sapiens modifications: 
Protein-Protein Analysis 
To identify human peptide/proteins presented in saliva we preformed the second 
search approach as described before to all of the subjects. Clinical characteristics of 
the subjects enrolled in this study are presented in Table VI: head and neck cancer 
patients and 10 healthy control subjects. After submitted the samples to nanoHPLC 
separation and MS/MS spectra analysis peptides and proteins were identified with 
Mascot software and emPAI values were collected for each subject. 123 salivary 
proteins were identified and divided according to the different groups established 
before. Figure 7 illustrates the distribution of identified proteins per group. More 
detailed schemes can be found in the supplementary figures. 
 
 
 
From all of the salivary proteins detected only 19 were common to all of studied 
subjects including proline rich-proteins, histatin 1, mucin 7, SMR3B protein, 
statherins, cathepsins, H2A2A and H4 histone, cytoplasmic actin, fibrinogen beta 
chain, hemoglobin, lactotransferrin and the S100A9 protein. These common proteins 
are mainly involved in the salivary processes specified in Table X.  
Figure 7 - Protein 
distribution by control 
and cancer groups. 
Analysis preformed with 
Venny 
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Table X - Most abundant proteins in studied saliva samples and they're biological function 
Protein Biological Function 
ACTB Platelet aggregation, Retina Homeostasis 
Cathepsin G Selection defence response to fungus, killing of 
cells of other organism, disruption of cells of other 
organism 
 
Fibrinogen beta 
chain 
Hemoglobin 
subunit beta 
Platelet aggregation, homotypic cell-cell adhesion 
Histatin 1 Defence response to fungus, killing of cells of other 
organism, disruption of cells of other organism 
Lactotransferrin Regulation of lipopolysaccharide-mediated signalling 
pathway, lipopolysaccharide-mediated signalling 
pathway 
 
Basic salivary 
proline-rich 
protein 3 
Defence response to bacterium 
S100A9 Regulation of lipopolysaccharide-mediated signalling 
pathway, defence response to fungus, inflammatory 
processes 
 
Statherin Regulation of bone mineralization and biomineral tissue 
development 
Zymogen granule 
protein 16 
homolog B 
Retina homeostasis (carbohydrate binding) 
 
 
From the distribution scheme from figure 7 unique proteins to each group were 
identified, protein-protein interaction was analysed and we correlate several cellular 
pathways with saliva proteome.  
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It was possible to identify 4 proteins exclusive to Control Group (Blue), 25 proteins 
exclusive to Larynx group (yellow), 16 proteins exclusive to Pharynx and Oral 
Cavity and none exclusive to Nasopharynx and Nostrils Group. 
Protein-protein interaction was preformed with Cytoscape and Go Clue and 5 main 
clusters were identified. In figure 8 it is possible to identify five clusters  
 
 
Figure 8 - Protein- protein interaction from the unique proteins found in figure 7 were 
preformed with Cytoscape and CluePedia. Yellow clusters belong mainly to larynx group and 
green cluster belong mainly to pharynx and oral cavity group. Yellow dots are proteins from 
the larynx group, green dots are proteins from Pharynx and Oral Cavity group and Blue dots 
are proteins from Control group 
 
with biological functions like retina homeostasis, platelet degranulation, regulation 
of interleukin – 1 beta production, chromatin assembly and chromatin remodelling 
ate centromere.  
The cluster in green has genes that encode proteins mainly from Pharynx and Oral 
Cavity group (green) and with one gene from Control group (blue). This cluster is 
composed by 8 genes from which 5 share functions with other clusters. Genes like 
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ALDOA, BRPF3 and CAP1 encode proteins that have mainly functions in platelet 
degranulation; shared genes with retina homeostasis cluster like ALB and FGA also 
encode proteins that regulates heterotypic cell-cell adhesion and negative regulation 
of extrinsic apoptotic signalling pathway via death domain receptors. APOA1, 
COL1A1 and HMGB2 share functions with regulation of interleukin-1 beta 
production cluster and have biological functions in positive regulation of substrate 
adhesion-dependent cell spreading, positive regulation of cell morphogenesis 
involved in differentiation, regulation in collagen catabolic process, negative 
regulation of extrinsic apoptotic signalling pathway via death domain receptors and 
also in regulation of heterotypic cell-cell adhesion.  
HMGB2 has also chemo attractant activity binding proteins associated with 
chromatin and single stranded DNA and it also has the ability to bend DNA. 
Additionally is possible to identify several yellow clusters mainly from the Larynx 
group (yellow). The biggest cluster is constituted by six genes mainly with the 
biological function of regulation of interleukin – 1 beta production.  
From the six genes, APOA1 and COL1A1 have shared functions with platelet 
degranulation cluster and B2M and HSPB1 with retina homeostasis cluster. Besides 
the retina homeostasis functions, B2M and HSPB1 proteins also play roles in 
leukocyte mediated cytotoxicity and positive regulation of tumour necrosis factor 
biosynthetic process.  
AZU and ELANE limited to this cluster have biological functions in the positive 
regulation of tumour necrosis factor biosynthetic process and in regulation of 
chemokine biosynthetic process. 
Three genes compose the smaller yellow cluster, the retina homeostasis cluster: 
B2M, ACTG1, HSPB1 (described before) with platelet aggregation functions. 
The last cluster is composed by eight genes that encodes proteins from Larynx group 
and Pharynx and Oral Cavity group and one shared gene with platelet degranulation 
cluster from Pharynx and Oral Cavity group proteins and have main biological 
functions in chromatin assembly and chromatin remodelling at centromere  - Figure 
9. 
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From the eight exclusive gens to this cluster HIST1H1D (Histone H1.3), 
HIST1H2BH (Histone H2B type 1-H) and HIST1H2BO (Histone H2B type 1-O)  
 
 
 
 
 
 
 
 
 
 
belong to Pharynx and Oral Cavity group and HIST1H1E (Histone H1.4), 
HIST2H2BE, HIST1H2BM, CENPV (Centromere protein V) and SMARCA5 
(SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily A member 5) belong to Larynx group. 
HIST1H1D encodes for proteins with functions in nucleosome positioning and 
assembling by forming the chromatin fibber regulating the transcription. Post 
translational modifications in Histones H1 usually are phosphorylations during 
phases G2 and M in cell cycle and dephosphorylated sharply after. 
HIST1H2BH and HIST1H2BO is a core component of the nucleosome, playing a 
central role trough chromatin organization in transcription regulation, DNA repair, 
DNA replication and chromosomal stability.  
From the Larynx group CENPV is a protein required in the centromeric formation 
and organization once is responsible for the distribution pericentromeric 
heterochromatin in interphase, in mitosis.  
Figure 9 - Cluster with proteins from Larynx group 
(yellow) and Pharynx and Oral Cavity group (green) 
  
   54 
SMARCA5 is a helicase that processes ATP-dependent nucleosome-remodelling 
activity. Complexes with this gene are capable of forming ordered nucleosome 
arrays on chromatin which requires H4 histones and are required in S phase for 
replication of pericentric heterochromatin and is a an essential component of the 
WICH complex that regulates the transcription of various genes and mediates the 
histone H2AX phosphorylation. 
HIST2H2BE besides the DNA binding activity similar with the histones described 
before has a broad antibacterial activity especially against Gram-Positive bacteria’s 
creating an innate immune response in mucosa. HIST1H1E and HIST1H2BM 
similar with HIST1H2BO is also a core component of the nucleosome, which will 
warp and compact the DNA into chromatin, it will also have a central role in the 
transcription regulation, DNA repair, DNA replication and chromosomal stability. 
All of these proteins from this cluster are correlated with the cell cycle formation. 
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Peptide Analysis 
Sequences of the peptides were also studied, a total of 1885 peptide sequences were 
identified and 104 sequences were found to be common to the four different groups, 
168 sequences were found only in Control group, 436 only in Larynx group, 430 
only in Pharynx and Oral Cavity group, 59 in Nasopharynx and Nostrils Group and 
14 sequences were common to all of the cancer groups – Figure 10. 
 
 
 
Figure 10 – Peptide distribution by group. Analysis was performed with resource to Venny 
 
Sequences common to all of the groups predominantly belong to salivary proteins 
like proline rich-proteins, histatin 1, mucin 7, SMR3B protein, statherins, cathepsins, 
H2 and H4 histone, actin, fibrinogen beta chain and hemoglobin.  
It was possible to identify 168 peptides exclusive to Control Group (Blue), 436 
peptides exclusive to Larynx group (yellow), 430 peptides exclusive to Pharynx and 
Oral Cavity and 59 peptides exclusive to Nasopharynx and Nostrils Group. 
In order to evaluate the proteolitic activity between control and all types of cancers 
the number peptide sequences of each studied individual were counted and 
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associated by type of cancer and by cancer groups established before. In Graphic 1 
we can observe the average number of unique sequences for each type of cancer and 
for controls: 
 
Graphic 1 - Comparation of the distribution of the number of unique sequences by cancer 
against control 
 
 
In Graphic 2 we can observe the average number of unique sequences for cancer 
groups established before and for controls: 
 
Graphic 2 - Comparation of the distribution of unique sequences by the groups established 
before. 
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To each type of cancer aminoacids of the terminal-N and terminal-C of the peptide 
residues were selected by the highest number of clivage repeats.  In Merops 
peptidase database, terminal-N and terminal-C residues were searched and tables 
with the possible salivary proteases were created in order to predict the proteolitic 
events in saliva of our patients (supplementary tables). 
In order to normalize the number of cleavages for each type of cancer a clivage ratio 
was created dividing the number of cleavages for the number of peptide sequences 
of all samples. Then in each type of cancer for each type of peptidase, frequency 
values were created and compared by each type of cancer – Graphic 3. 
Peptidases found were compared between cancers and controls and we could 
observe that the most abundant peptidases in our samples are cathepsins B, S and L 
and Pepsin A. 
Graphic 3 - Peptidase distribution by type of cancer 
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Comparing the peptidases found by cancer site against controls it was possible to 
observe that larynx and oropharynx have a higher proteolitic activity than controls. 
We can also observe that Cathepsin X wasn’t present in the control group and was 
present in all cancer types. 
The rest of the cancers doesn’t exhibit distinguish values from the control group. 
 
 
  
  
   60 
13. Discussion  
 
13.1 First search approach: Virus: 
As we have seen before cancer evolve through a series of somatic mutations that will 
induce cytogenetic changes resulting in uncontrolled cellular proliferation(111, 112). 
According to IARC there are several risk factors like alcohol, tobacco or virus that 
can increase the probability of breeding a cancer. 
In order to be possible to associate a specific to human cancer in 1990 epidemiologic 
and virologic guidelines were established, this way it is possible to relate a cancer to 
a virus if the prevention of infection (vaccination) or the delay of the time infection 
decreases the incidence of the tumour; if the virus in vitro is able to transform 
normal cells into malignant cells; if the virus genome or DNA is demonstrated only 
in tumour cells and not in normal cells and if the virus is able to induce tumour in 
experimental animals and if its neutralization prevents the tumour 
development(113). 
Several studies indicate that the most frequently associated virus to oral cancer 
progression and transformation have been Herpes group virus, HPV (114, 115), 
adenoviruses (116) and hepatitis C (117, 118). Despite human oncogenic viruses 
exploit different strategies that will contribute to cancer progression and 
development, they all share the propensity to establish long-term persistent 
infections using evading strategies to avoid the host immune response(113). 
In our study it was possible to identify several viral peptides in saliva from different 
types of viruses (including animal viruses), however none of the control subjects 
presented any type of viral peptide, which fulfil one of the guidelines established 
before. In table XI it is possible to prevent a strength of association between the 
viruses found and the patient cancers according with published researches. 
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Virus Tumour Association with literature 
Acanthamoeba 
polyphaga mimivirus 
Laryngeal SCC 
Related with pneumonia infections; 
no association found with cancers 
(119-121) * 
 
Bluetongue virus Laryngeal SCC 
Predominant in ruminants; Several 
studies in human cancer cells 
suggests this virus have cytotoxic 
effects and can induce apoptosis 
(122-124) * 
 
Avian encephalomyelitis 
virus 
Laryngeal SCC 
Related to hepatitis A; possesses 
motifs characteristic of H-rev107 
proteins involved in cell 
proliferation; modulate apoptosis 
(125-127) * 
 
Gallid herpesvirus 2 
(Avian herpesvirus 1) 
Nostrils 
oncogenic herpesvirus in chickens 
that causes  lymphoma; like human 
lymphoma chicken lymphoma cells 
overexpress the CD30 antigen; 
similar Epstein-Barr and herpesvirus-
6;  interacts directly with p53 and 
inhibits p53-mediated transcriptional 
activity and apoptosis (128-131) * 
 
Jembrana disease virus Nostrils 
similar to bovine immunodeficiency 
virus;  owns genes in common with 
HIV (132, 133) * 
 
Suid herpesvirus 1 
Laryngeal SCC 
Pharyngeal SCC 
Oropharyngeal 
SCC 
Similar to herpesvirus, there aren’t 
any studies in human cellular lines 
African swine fever virus Laryngeal SCC 
The ORF A179L of the virus is 
similar to proto-oncogene bcl-2; and 
in HeLa (human), myeloid leukaemia 
cell line K562 (human) and BSC-40 
(monkeys) cell lines protects cells 
from programmed cell death (134, 
135) * 
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Equine arteritis virus Laryngeal SCC 
causes respiratory and reproductive 
disease in horses; induces apoptosis 
initiated by caspase-8 activation and 
mitochondria-dependent caspase-9 
activation; despite infect HeLa cells 
persistently there are no studies 
relating the virus with cancers (136-
138) * 
 
Equid herpesvirus 2 
(equine cytomegalovirus) 
Laryngeal SCC 
Differs substantially from equine 
herpesvirus 1 and 3; induces 
oncogenic transformation in hamster 
embryo cells (139, 140) * 
 
 Equid herpesvirus 4 
Mouth floor SCC 
Oropharyngeal 
SCC 
Induces equine respiratory diseases; 
similar to equine herpesvirus 1; no 
association found with cancers (141) 
 
Murine polyomavirus Laryngeal SCC 
Has oncogenic properties in murines; 
belongs to the family of 
polyomavirus; human polyomavirus 
induces tumours (142, 143) * 
 
Feline immunodeficiency 
virus 
Laryngeal SCC 
Causes immune deficiency in cats; 
can infect humans but enters in latent 
stage; it’s a possible vector that can 
be used against human cancers (144, 
145) * 
 
Grapevine leafroll-
associated virus 3 
Uvula and Soft 
palate SCC 
Transmitted by bugs to grapevines; 
no association found with cancers 
(146, 147) 
 
Turnip yellow mosaic 
virus 
Laryngeal SCC 
Hypopharyngeal 
SCC 
Infects green vegetables; no 
association found with cancers (148) 
 
Paramecium bursaria Uvula and Soft Infects green algae; no association 
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Chlorella virus 1 palate SCC found with cancers (149, 150) 
 
Human enterovirus 71 
Uvula and Soft 
palate SCC 
Pathogen of hand-foot-and-mouth 
disease; associated with severe 
neurological disease; no association 
found with cancers (151) 
 
Measles Virus (rubeola) Laryngeal SCC 
Causes contagious respiratory 
infection; no association found with 
cancers (152) 
 
Rubella virus Laryngeal SCC 
Similar to measles; provoke severe 
rashes; no association found with 
cancers (152) 
 
Dengue virus Laryngeal SCC 
Mosquito-borne disease; lead to 
massive bleeding, shock, and death; 
doesn’t increase tumour necrosis 
factor-α-induced permeability; no 
association found with cancers (153) 
 
Influenza A virus 
Laryngeal SCC 
Nostrils 
Flu with respiratory complications; 
no association found directly with 
cancer (154, 155) 
 
Influenza B virus 
Pharyngolaryngeal 
SCC 
Similar to influenza A (154, 155) 
 
Hepatitis C virus 
Mouth floor SCC 
 
Type 1 carcinogenic agent by IARC; 
oncogenic virus 
Induces hepatocellular cancer; 
 
Human herpesvirus 1 Laryngeal SCC 
Related to several cancers; not 
related to cancer Laryngeal cancer 
 
Epstein-Barr virus 
(human herpesvirus 4) 
Vocal Chords 
SCC 
Related to nasopharyngeal 
Carcinoma; EBNA 3 (the protein 
found) is essential for B-cells 
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Tab
le 
XI - 
Vir
uses 
asso
ciat
ed 
with viral peptides and association with current literature 
 
 
Relating a virus to cancer is a complicated process with several difficulties 
associated. The fact of the human host to be unique, immune system status, single 
genetic characteristics at molecular level and the age at the time of the infection turn 
this multistep progress disease hard to follow and associate to virus.   Also causes of 
cancer may vary by geographical areas and most related cancers need co-factors for 
progression(113).  
Other factors to have in consideration are the different oncogenic potential in 
different strains (ex. HPV), the long incubation time between infection and the 
cancer and the inability to reproduce many human cancers with the virus in study in 
experimental animals(113). 
As it was possible to verify in our state of the art, there are several viruses that have 
the capability to induce the lost of control in normal cells and change them into 
tumoural cells. In addiction, we also saw that several viral infections like HIV can 
diminish the immunitary system functions and its capacity to detect and destroy 
possible carcinogenic cells. 
In our study we didn’t find any viral peptides in the control group, which fulfil one 
of the guidelines to relate a virus to a cancer, this lead us to think that probably even 
the animal viruses that we found could contribute in any unknown way to 
transformation and EBV 
immortalization; overtake the pRb 
check points in the cell cycle (34) 
 
Human cytomegalovirus 
(Human herpesvirus 5) 
Laryngeal SCC 
Hypopharyngeal 
SCC 
Infection arises in cancer patients due 
to compromised immunitary system  
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mutagenesis or could compromise the normal immune system function allowing a 
easier cancer development. 
Despite we couldn’t correlate the viruses with the specific cancers sites of our 
patients it lead us to think if there are animal viruses that can be starting to induce 
changes in human cells once some of them have the capability to modulate apoptosis 
protecting the cell from a programed death.  
We found several animal viruses with similar proteins to human viruses and human 
proto-oncogenes like Avian encephalomyelitis virus similar to Hepatitis A, Jembrana 
disease virus similar to Human immunodeficiency virus or the ORF A179L from 
African swine fever virus similar to bcl-2 
Animal virus should not be able to disarray human cells once they enter in human 
system and usually stay in latency state, not causing any signs of symptoms of the 
animal disease in humans. However viruses usually suffer several mutations 
evolving and unknown strains are constantly being created. 
In the case of the Gallid herpesvirus 2 (Avian herpesvirus 1), an oncogenic viruses 
causing nasal cancer in chickens and with similar proprieties to EBV, known to 
provoke nasopharyngeal carcinomas in humans, the cancer development site is the 
same in the chickens and in the humans. We couldn’t found more studies that could 
relate the virus specifically to human cancer. 
Still we also found viruses like the Feline immunodeficiency virus that due to its 
similarity to human viruses are starting to be manipulated and used like vectors in 
new cancer researches to infect the cancer cells and destroy them. 
This is the first study relating viral peptides and saliva from head and neck cancer 
patients until today and we expect that will come to contribute to new non-invasive 
methods of prognosis or risk trough saliva that can measure viruses as biomarkers. 
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13.2 Second search approach: Homo sapiens modifications: 
Our study compares the salivary proteome between controls and head and neck 
cancer patient, allowing the foreseeing of potential disease biomarkers with 
diagnosis and prognosis significance and the future elucidation of disease 
pathogenesis.  
From the 123 proteins identified in the saliva of all subjects studied only 3 proteins 
were exclusively assigned to cancer patients. Analysis with STRING bioinformatics 
tool suggests their involvement in condensation of nucleosome chains into higher 
order structures, cytoskeleton organization and oxygen transportation to peripheral 
tissues. Actually clinical studies in prostate and breast relate the involvement of 
Histones 1 (Histone H1.5) as a possible diagnostic biomarker(156, 157). 
The analysis of salivary proteins unique by group revealed four distinct clusters. 
Mainly composed by proteins from pharynx and oral cavity group we have found the 
platelet degranulation cluster, which is a biological process related to blood 
homeostasis with association to malignant diseases since the 19th century (158). 
Platelets are activated when an injury occurs to prevent fatal bleedings; a growing 
tumour is dependent on angiogenesis for oxygen and nutrient supply as well as for 
removal of waste products. Platelets are also metastasis regulators (158). 
Mainly composed by proteins from the Larynx group we have found a cluster related 
with regulation of Interleukin-1 beta production. Interleukins are cytokines with 
central roles in regulation of immune and inflammatory responses, several studies 
show different opinions on whether this cytokine is related to oral cancer or not. A 
study from 2007 studied the +3953 C/T polymorphism and conclude that 
interleukin-1 beta doesn’t play a primary role in this malignancy since there are 
other interleukins with more prominent effects(159). However a study from 2013 
preformed in unstimulated whole saliva in OSCC patients pre and pos-operation 
detected different cytokine concentration concluding that might be a useful tool in 
early stages detection(160). 
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Another significant cluster it was a cluster composed mainly with proteins from 
larynx and pharynx and oral cavity groups related to chromatin functions composed 
mainly by Histones 1 and Histones 2. 
The fundamental unit of chromatin, the nucleosome is composed by an octamer of 
histones from types H2A, H2B, H3 and H4, this structure affects primarily the 
wrapping of DNA and then the replication, transcription and the enzymes involved 
in the process(161). Monteiro et all relate different types of cancer with different 
types of H2 histones Chen et all was able to associate several Histones 3 to different 
prognosis in Oral squamous cell carcinoma(162). Histones can also suffer post-
translational mutations that can alter the chromatin structure and gene transcription 
originating several variants. The variants so far associated to oral cancer are H3.3 
and H2A.X (163). In histones cluster is it possible to identify one protein – 
SMARCA5 – one essential component to the WICH complex that regulates H”AX 
phosphorylation which lead us to believe that this cluster might have histones that 
can be used in the future as biomarkers to our cancers. One of our patients presented 
the protein to H2A.X however since it was the only one and our analysis are based 
in the proteins present in at least two individuals that result could not be verified and 
wasn’t considered in the analysis.  
In our study we also preformed the peptides analysis in order to disclosure peptide 
with more abundance and the potential associated salivary proteases to head and 
neck cancers. We intend to see if the cancer patients suffer from more proteolitic 
activity than the control patients since in our state of the art we have found some 
studies relating the rate of proteolysis with certain diseases. 
It was possible to identify that most of the common sequences of our patients belong 
to proteins with salivary functions. 
Most of the types of cancer present a higher number of unique sequences than 
controls, the cancer type that we have found with more unique sequences was the 
pharyngolarynx cancer, however, we must take under consideration that our cancers 
have different numbers of patients which are unique and once one person can 
present more peptides and proteins in saliva than other. 
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Proteolytic analysis revealed several proteases, the most common were: Cathepsins 
(B, D, E, K, L and X), Elastase-2, Matrix metallopeptidases 2 and 9, Rhizopuspesin 
and pepsin A. 
Comparing each cancer to the control group we have found that larynx and 
oropharynx samples suffers more cleavage than the control group.  
A proteolytic analysis from Schmidt et all in tissue samples from OSCC patients 
revealed matrix metallopeptidase-9 increased the gelatinolytic and fibrinolytic 
activity in tumour samples (164). In our samples for matrix metallopeptidase -9 the 
cleavage ratio was higher than controls in Nasopharynx and Larynx cancer. 
 This analysis could indicate a possible biomarker by cleave rate for these specific 
cancers. 
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14. CONCLUDING REMARKS 
This work addresses the first exploratory study regarding salivary proteases and 
peptidome with head and neck cancer patients. Results lead us to think in each way 
animal viruses are implicated in some human cancers and if they’re latency state 
help in the development of cancer. 
Proteolytic analysis revealed that maybe it would be possible to detect larynx and 
oropharynx cancers in previous stages but we need further studies to comprise that. 
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2. ATTACHMENTS:  
2.1 Description of the proteins found and respective acronym. 
Protein Description 
6PGD_HUMAN 6-phosphogluconate dehydrogenase, decarboxylation 
ACTA_HUMAN Actin, aortic smooth muscle 
ACTB_HUMAN Actin, cytoplasmic 
ACTG_HUMAN Actin, cytoplasmic 2  
ALBU_HUMAN Serum albumin  
AMY1_HUMAN Alpha-amylase 1  
AMYP_HUMAN Pancreatic alpha-amylase  
ANXA1_HUMAN Annexin A1  
APOA1_HUMAN Apolipoprotein A-I  
ATOH1_HUMAN Protein atonal homolog 1  
B2MG_HUMAN Beta-2-microglobulin  
BPIA2_HUMAN BPI fold-containing family A member 2  
BPI_HUMAN Bactericidal permeability-increasing protein 
BPIB1_HUMAN BPI fold-containing family B member 1  
BRPF3_HUMAN Bromodomain and PHD finger-containing protein 3  
CAH6_HUMAN Carbonic anhydrase 6  
CAP7_HUMAN Azurocidin  
CENPV_HUMAN Centromere protein V  
CATG_HUMAN Cathepsin G  
CD040_HUMAN Uncharacterized protein  
CO1A1_HUMAN Collagen alpha-1 (I) chain  
COBL_HUMAN Protein cordon-bleu  
CRNN_HUMAN Cornulin  
CYTB_HUMAN Cystatin-B  
CYTN_HUMAN Cystatin-SN  
ELNE_HUMAN Neutrophil elastase 
ENOA_HUMAN Alpha-enolase  
EZRI_HUMAN Ezrin  
FIBA_HUMAN Fibrinogen alpha chain 
FIBB_HUMAN Fibrinogen beta chain  
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase 
H11_HUMAN Histone H1,1  
H12_HUMAN Histone H1,2  
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H13_HUMAN Histone H1,3  
H14_HUMAN Histone H1,4  
H15_HUMAN Histone H1,5  
H2A1B_HUMAN Histone H2A type 1-B/E  
H2A1C_HUMAN Histone H2A type 1-C  
H2A1H_HUMAN Histone H2A type 1-H  
H2A2A_HUMAN Histone H2A type 2-A  
H2A2B_HUMAN Histone H2A type 2-B  
H2A2C_HUMAN Histone H2A type 2-C  
H2AJ_HUMAN Histone H2A,J  
H2B1B_HUMAN Histone H2B type 1-B  
H2B1C_HUMAN Histone H2B type 1-C/E/F/G/I  
H2B1D_HUMAN Histone H2B type 1-D  
H2B1H_HUMAN Histone H2B type 1-H  
H2B1J_HUMAN Histone H2B type 1-J  
H2B1K_HUMAN Histone H2B type 1-K  
H2B1M_HUMAN Histone H2B type 1-M  
H2B1O_HUMAN Histone H2B type 1-O  
H2B2E_HUMAN Histone H2B type 2-E  
H2B3B_HUMAN Histone H2B type 3-B  
H2BFS_HUMAN Histone H2B type F-S  
H31_HUMAN Histone H3,1 
H31T_HUMAN Histone H3,1t  
H4_HUMAN Histone H4  
HBA_HUMAN Hemoglobin subunit alpha  
HBB_HUMAN Hemoglobin subunit beta  
HIS1_HUMAN Histatin-1  
HIS3_HUMAN Histatin-3  
HMGB2_HUMAN High mobility group protein B2  
HMGN2_HUMAN Non-histone chromosomal protein HMG-17  
HNRL1_HUMAN Heterogeneous nuclear ribonucleoprotein U-like protein 1  
HS902_HUMAN Putative heat shock protein HSP 90-alpha A2  
HSPB1_HUMAN Heat shock protein beta-1  
INF2_HUMAN Inverted formin-2  
K1C13_HUMAN Keratin, type I cytoskeletal 13  
K2C4_HUMAN Keratin, type II cytoskeletal 4  
K2C6A_HUMAN Keratin, type II cytoskeletal 6A  
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K2C6B_HUMAN Keratin, type II cytoskeletal 6B  
LEG7_HUMAN Galectin-7  
MAMD1_HUMAN Mastermind-like domain-containing protein 1  
MNDA_HUMAN Myeloid cell nuclear differentiation antigen 
MUC7_HUMAN Mucin-7  
NAV2_HUMAN Neuron navigator 2  
PIGR_HUMAN Polymeric immunoglobulin receptor  
PIP_HUMAN Prolactin-inducible protein  
PRB2_HUMAN Basic salivary proline-rich protein 2  
PRB3_HUMAN Basic salivary proline-rich protein 3  
PRB4_HUMAN Basic salivary proline-rich protein 4  
PROL4_HUMAN Proline-rich protein 4  
PRP1_HUMAN Basic salivary proline-rich protein 1  
PRPC_HUMAN Salivary acidic proline-rich phosphoprotein 1/2  
S10A8_HUMAN Protein S100-A8  
S10A9_HUMAN Protein S100-A9  
S10AC_HUMAN Protein S100-A12  
SET1B_HUMAN Histone-lysine N-methyltransferase SETD1B  
SMCA5_HUMAN SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily A member 5  
SMR3B_HUMAN Submaxillary gland androgen-regulated protein 3B  
STAT_HUMAN Statherin  
THIO_HUMAN Thioredoxin  
TRFL_HUMAN Lactotransferrin  
TYB4_HUMAN Thymosin beta-4  
VASP_HUMAN Vasodilator-stimulated phosphoprotein  
ZG16B_HUMAN Zymogen granule protein 16 homolog B  
SPRR3_HUMAN Small proline-rich protein 3 
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Table of the identified proteins in at least 2 individuals by group 
Proteins in 
Control 
Group (30) 
Proteins in Larynx 
Group (66) 
Proteins in 
Pharynx and Oral 
Cavity Group (53) 
Proteins in 
Nasopharynx and 
Nostrils Group 
(24) 
ACTB_HUMAN 
ALBU_HUMAN 
AMY1_HUMAN 
ANXA1_HUMAN 
BPIB1_HUMAN 
CATG_HUMAN 
CRNN_HUMAN 
CYTB_HUMAN 
CYTN_HUMAN 
FIBB_HUMAN 
G3P_HUMAN 
H2A2A_HUMAN 
H2B1D_HUMAN 
H4_HUMAN 
HBB_HUMAN 
HIS1_HUMAN 
K1C13_HUMAN 
MUC7_HUMAN 
PIP_HUMAN 
PRB2_HUMAN 
PRB3_HUMAN 
PRB4_HUMAN 
PRP1_HUMAN 
PRPC_HUMAN 
S10A9_HUMAN 
SMR3B_HUMAN 
STAT_HUMAN 
THIO_HUMAN 
TRFL_HUMAN 
ZG16B_HUMAN 
ACTB_HUMAN 
ACTG_HUMAN 
AMY1_HUMAN 
AMYP_HUMAN 
ANXA1_HUMAN 
ATOH1_HUMAN 
B2MG_HUMAN 
BPIA2_HUMAN 
BPIB1_HUMAN 
CAH6_HUMAN 
CAP7_HUMAN 
CENPV_HUMAN 
CATG_HUMAN 
CD040_HUMAN 
CO1A1_HUMAN 
CRNN_HUMAN 
CYTN_HUMAN 
ELNE_HUMAN 
EZRI_HUMAN 
FIBB_HUMAN 
G3P_HUMAN 
H12_HUMAN 
H14_HUMAN 
H15_HUMAN 
H2A1C_HUMAN 
H2A1H_HUMAN 
H2A2A_HUMAN 
H2B1B_HUMAN 
H2B1M_HUMAN 
H2B2E_HUMAN 
H2BFS_HUMAN 
H31_HUMAN 
H31T_HUMAN 
H4_HUMAN 
ACTB_HUMAN 
ACTBL_HUMAN 
ALDOA_HUMAN 
AMY1_HUMAN 
APOA1_HUMAN 
BPIB1_HUMAN 
BRPF3_HUMAN 
CAP1_HUMAN 
CATG_HUMAN 
CD040_HUMAN 
COBL_HUMAN 
CRNN_HUMAN 
FIBA_HUMAN 
FIBB_HUMAN 
G3P_HUMAN 
H12_HUMAN 
H13_HUMAN 
H15_HUMAN 
H2A1C_HUMAN 
H2A2A_HUMAN 
H2AJ_HUMAN 
H2B1B_HUMAN 
H2B1D_HUMAN 
H2B1H_HUMAN 
H2B1O_HUMAN 
H31_HUMAN 
H4_HUMAN 
HBA_HUMAN 
HBB_HUMAN 
HBD_HUMAN 
HIS1_HUMAN 
HIS3_HUMAN 
HMGB2_HUMAN 
LEG7_HUMAN 
ACTB_HUMAN 
CATG_HUMAN 
FIBB_HUMAN 
G3P_HUMAN 
H15_HUMAN 
H2A2A_HUMAN 
H4_HUMAN 
HBA_HUMAN 
HBB_HUMAN 
HIS1_HUMAN 
MUC7_HUMAN 
PIGR_HUMAN 
PRB2_HUMAN 
PRB3_HUMAN 
PRB4_HUMAN 
PRP1_HUMAN 
PRPC_HUMAN 
S10A9_HUMAN 
SMR3B_HUMAN 
STAT_HUMAN 
TRFL_HUMAN 
TYB4_HUMAN 
ZG16B_HUMAN 
SPRR3_HUMAN 
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HBA_HUMAN 
HBB_HUMAN 
HIS1_HUMAN 
HIS3_HUMAN 
HMGN2_HUMAN 
HNRL1_HUMAN 
HSPB1_HUMAN 
K2C4_HUMAN 
K2C6B_HUMAN 
LEG7_HUMAN 
MAMD1_HUMAN 
MNDA_HUMAN 
MUC7_HUMAN 
PIGR_HUMAN 
PIP_HUMAN 
PRB2_HUMAN 
PRB3_HUMAN 
PRB4_HUMAN 
PROL4_HUMAN 
PRP1_HUMAN 
PRPC_HUMAN 
S10A8_HUMAN 
S10A9_HUMAN 
S10AC_HUMAN 
SMCA5_HUMAN 
SMR3B_HUMAN 
STAT_HUMAN 
TRFL_HUMAN 
TYB4_HUMAN 
VASP_HUMAN 
ZG16B_HUMAN 
SPRR3_HUMAN 
MNDA_HUMAN 
MUC7_HUMAN 
PRB2_HUMAN 
PRB3_HUMAN 
PRB4_HUMAN 
PROL4_HUMAN 
PRP1_HUMAN 
PRPC_HUMAN 
PRC2C_HUMAN 
S10A8_HUMAN 
S10A9_HUMAN 
S10AC_HUMAN 
S2541_HUMAN 
SET1B_HUMAN 
SMR3B_HUMAN 
STAT_HUMAN 
TRFL_HUMAN 
TYB4_HUMAN 
ZG16B_HUMAN 
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Venn Diagrams showing the distribution of the identified proteins between the 
Control group and the Larynx group 
 
 
Table of the distribution of the identified proteins between the Control group and the 
Larynx group 
 
Proteins only in 
Control Group (5) 
Proteins in Control Group 
and Larynx Group (25) 
Proteins only in Larynx 
Group (41) 
LBU_HUMAN 
CYTB_HUMAN 
H2B1D_HUMAN 
K1C13_HUMAN 
THIO_HUMAN 
ACTB_HUMAN 
AMY1_HUMAN 
ANXA1_HUMAN 
BPIB1_HUMAN 
CATG_HUMAN 
CRNN_HUMAN 
CYTN_HUMAN 
FIBB_HUMAN 
G3P_HUMAN 
H2A2A_HUMAN 
H4_HUMAN 
HBB_HUMAN 
HIS1_HUMAN 
MUC7_HUMAN 
PIP_HUMAN 
PRB2_HUMAN 
PRB3_HUMAN 
PRB4_HUMAN 
ACTG_HUMAN 
AMYP_HUMAN 
ATOH1_HUMAN 
B2MG_HUMAN 
BPIA2_HUMAN 
CAH6_HUMAN 
CAP7_HUMAN 
CENPV_HUMAN 
CD040_HUMAN 
CO1A1_HUMAN 
ELNE_HUMAN 
EZRI_HUMAN 
H12_HUMAN 
H14_HUMAN 
H15_HUMAN 
H2A1C_HUMAN 
H2A1H_HUMAN 
H2B1B_HUMAN 
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PRP1_HUMAN 
PRPC_HUMAN 
S10A9_HUMAN 
SMR3B_HUMAN 
STAT_HUMAN 
TRFL_HUMAN 
ZG16B_HUMAN 
H2B1M_HUMAN 
H2B2E_HUMAN 
H2BFS_HUMAN 
H31_HUMAN 
H31T_HUMAN 
HBA_HUMAN 
HIS3_HUMAN 
HMGN2_HUMAN 
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Venn Diagrams showing the distribution of the identified proteins between the 
Control group and the Pharynx + Oral Cavity group 
 
 
 
Table of the distribution of the identified proteins between the Control group and the 
Pharynx and Oral Cavity group 
Proteins only in 
Control Group (7) 
Proteins in Control Group 
and Pharynx and Oral 
Cavity Group (23) 
Proteins only in Pharynx 
+ Oral Cavity  (30) 
ALBU_HUMAN 
ANXA1_HUMAN 
CYTB_HUMAN 
CYTN_HUMAN 
K1C13_HUMAN 
PIP_HUMAN 
THIO_HUMAN 
 
ACTB_HUMAN 
AMY1_HUMAN 
BPIB1_HUMAN 
CATG_HUMAN 
CRNN_HUMAN 
FIBB_HUMAN 
G3P_HUMAN 
H2A2A_HUMAN 
H2B1D_HUMAN 
H4_HUMAN 
HBB_HUMAN 
HIS1_HUMAN 
MUC7_HUMAN 
PRB2_HUMAN 
PRB3_HUMAN 
PRB4_HUMAN 
PRP1_HUMAN 
ACTBL_HUMAN 
ALDOA_HUMAN 
APOA1_HUMAN 
BRPF3_HUMAN 
CAP1_HUMAN 
CD040_HUMAN 
COBL_HUMAN 
FIBA_HUMAN 
H12_HUMAN 
H13_HUMAN 
H15_HUMAN 
H2A1C_HUMAN 
H2AJ_HUMAN 
H2B1B_HUMAN 
H2B1H_HUMAN 
H2B1O_HUMAN 
H31_HUMAN 
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PRPC_HUMAN 
S10A9_HUMAN 
SMR3B_HUMAN 
STAT_HUMAN 
TRFL_HUMAN 
ZG16B_HUMAN 
 
HBA_HUMAN 
HBD_HUMAN 
HIS3_HUMAN 
HMGB2_HUMAN 
LEG7_HUMAN 
MNDA_HUMAN 
PROL4_HUMAN 
PRC2C_HUMAN 
S10A8_HUMAN 
S10AC_HUMAN 
S2541_HUMAN 
SET1B_HUMAN 
TYB4_HUMAN 
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Venn Diagrams showing the distribution of the identified proteins between the 
Control group and the Nasopharynx and Nostrils Group
 
 
 Table of the distribution of the identified proteins between the Control group and 
the Pharynx and Nasopharynx and Nostrils group 
 
Proteins only in Control 
Group (11) 
Proteins in Control 
Group and Nasopharynx 
and Nostrils Group (19) 
Proteins only in 
Nasopharynx and 
Nostrils Group (5) 
ALBU_HUMAN 
AMY1_HUMAN 
ANXA1_HUMAN 
BPIB1_HUMAN 
CRNN_HUMAN 
CYTB_HUMAN 
CYTN_HUMAN 
H2B1D_HUMAN 
K1C13_HUMAN 
PIP_HUMAN 
THIO_HUMAN 
 
ACTB_HUMAN 
CATG_HUMAN 
FIBB_HUMAN 
G3P_HUMAN 
H2A2A_HUMAN 
H4_HUMAN 
HBB_HUMAN 
HIS1_HUMAN 
MUC7_HUMAN 
PRB2_HUMAN 
PRB3_HUMAN 
PRB4_HUMAN 
PRP1_HUMAN 
PRPC_HUMAN 
S10A9_HUMAN 
SMR3B_HUMAN 
STAT_HUMAN 
TRFL_HUMAN 
ZG16B_HUMAN 
 
 
 
 
 
H15_HUMAN 
HBA_HUMAN 
PIGR_HUMAN 
TYB4_HUMAN 
SPRR3_HUMAN 
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2.2 Venn Diagrams showing the distribution of the identified proteins between 
the Control group, the Larynx group, the Pharynx and Oral Cavity group 
and the Nasopharynx and Nostrils group 
 
 
2.3 Table of the distribution of the identified proteins between Control group, 
the Larynx group, the Pharynx and Oral Cavity group and the 
Nasopharynx and Nostrils group 
Proteins only in 
Control Group (4) 
Proteins only 
in Larynx 
Group (25) 
Proteins only 
in Pharynx 
and Oral 
Cavity 
Group (16) 
Proteins 
common to 
all groups 
(19) 
Proteins 
common to 
all cancer 
groups (3) 
ALBU_HUMAN 
CYTB_HUMAN 
K1C13_HUMAN 
THIO_HUMAN 
 
ACTG_HUMAN 
AMYP_HUMAN 
ATOH1_HUMAN 
B2MG_HUMAN 
BPIA2_HUMAN 
CAH6_HUMAN 
CAP7_HUMAN 
CENPV_HUMAN 
CO1A1_HUMAN 
ELNE_HUMAN 
EZRI_HUMAN 
H14_HUMAN 
H2A1H_HUMAN 
ACTBL_HUMAN 
ALDOA_HUMAN 
APOA1_HUMAN 
BRPF3_HUMAN 
CAP1_HUMAN 
COBL_HUMAN 
FIBA_HUMAN 
H13_HUMAN 
H2AJ_HUMAN 
H2B1H_HUMAN 
H2B1O_HUMAN 
HBD_HUMAN 
HMGB2_HUMAN 
ACTB_HUMAN 
CATG_HUMAN 
FIBB_HUMAN 
G3P_HUMAN 
H2A2A_HUMAN 
H4_HUMAN 
HBB_HUMAN 
HIS1_HUMAN 
MUC7_HUMAN 
PRB2_HUMAN 
PRB3_HUMAN 
PRB4_HUMAN 
PRP1_HUMAN 
H15_HUMAN 
HBA_HUMAN 
TYB4_HUMAN 
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H2B1M_HUMAN 
H2B2E_HUMAN 
H2BFS_HUMAN 
H31T_HUMAN 
HMGN2_HUMAN 
HNRL1_HUMAN 
HSPB1_HUMAN 
K2C4_HUMAN 
K2C6B_HUMAN 
MAMD1_HUMAN 
SMCA5_HUMAN 
VASP_HUMAN 
PRC2C_HUMAN 
S2541_HUMAN 
SET1B_HUMAN 
PRPC_HUMAN 
S10A9_HUMAN 
SMR3B_HUMAN 
STAT_HUMAN 
TRFL_HUMAN 
ZG16B_HUMAN 
 
 
Venn Diagrams showing the distribution of the identified peptides between the 
Control group and the Larynx group 
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Venn Diagrams showing the distribution of the identified peptides between the 
Control group and the Pharynx and Oral Cavity group 
 
 
Venn Diagrams showing the distribution of the identified peptides between the 
Control group and the Nasopharynx and Nostrils group 
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2.4 Venn Diagrams showing the distribution of the identified peptides between 
Control group, the Larynx group, the Pharynx and Oral Cavity group and 
the Nasopharynx and Nostrils group 
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2.5 Proteases from the control terminal residues  
 
Terminal 
N Residue 
Clivages 
Ratio 
Peptidases 
Asp Gly 0,0281 pepsin A; Cathepsin B, Caspase 1, HIV-1 retropepsin 
Gln Gly 0,0276 Cathepsin L,S,K 
Tyr Gly 0,0244 Pepsina A; Cathepsin D,L,S,B 
Val Arg 0,0218 DegP peptidase; Cathepsin L; chymosin;rhizopuspepsin 
Ile Ala 0,0207 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Met Asn 0,0164 granzyme M, meprin beta subunit, Cathepsin B, E, L, K, S 
Gly Pro 0,0122 aminopeptidase P, cathepsin B, L3, matrix metallopeptidase, ubiquitin-specific 
peptidase 4 and 15 
Ile Arg 0,0111 pepsin A, rhizopuspepsin, cathepsin L, calpain-1 and 2, elastase-2 
Pro Pro 0,0111 Cathepsin L1 and L3, lactocepin I, calpain 1 and 2 
Ser Asp 0,0095 pepsin A, aspergillopepsin I, necepsin 1 and 2, cathepsin L and S 
Phe Gly 0,0090 pepsin A and B, cathepsin D, E and L, necepsin 1, HIV-1 retropepsin,  
chymotrypsin A 
 
 
Terminal 
N 
Residue 
Clivages 
Ratio 
Peptidases 
Asp Gly 0,0281 pepsin A; Cathepsin B, Caspase 1, HIV-1 retropepsin 
Gln Gly 0,0276 Cathepsin L,S,K 
Tyr Gly 0,0244 Pepsina A; Cathepsin D,L,S,B 
Val Arg 0,0218 DegP peptidase; Cathepsin L; chymosin;rhizopuspepsin 
Ile Ala 0,0207 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Met Asn 0,0164 granzyme M, meprin beta subunit, Cathepsin B, E, L, K, S 
Gly Pro 0,0122 aminopeptidase P, cathepsin B, L3, matrix metallopeptidase, ubiquitin-specific 
peptidase 4 and 15 
Ile Arg 0,0111 pepsin A, rhizopuspepsin, cathepsin L, calpain-1 and 2, elastase-2 
Pro Pro 0,0111 Cathepsin L1 and L3, lactocepin I, calpain 1 and 2 
Ser Asp 0,0095 pepsin A, aspergillopepsin I, necepsin 1 and 2, cathepsin L and S 
Phe Gly 0,0090 pepsin A and B, cathepsin D, E and L, necepsin 1, HIV-1 retropepsin,  
chymotrypsin A 
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2.6  Proteases from the terminal residues by cancer 
 
Laryngeal SCC 
 
Terminal 
N 
Residue 
Clivages 
Ratio 
Peptidases 
Gln Gly 0,1427 Cathepsin L,S,K 
Met Asn 0,0621 granzyme M, meprin beta subunit, Cathepsin B, E, L, K, S 
Tyr Gly 0,0605 Pepsina A; Cathepsin D,L,S,B 
Arg Gly 0,0361 rhizopuspepsin, memapsin-1, yapsin A, cathepsin B, L and K 
Phe Gly 0,0334 pepsin A and B, cathepsin D, E and L, necepsin 1, HIV-1 retropepsin,  
chymotrypsin A 
Ile Met 0,0308 elastase-2, matrix metallopeptidase-2 
Asp Gly 0,0297 pepsin A; Cathepsin B, Caspase 1, HIV-1 retropepsin 
Pro Pro 0,0281 Cathepsin L1 and L3, lactocepin I, calpain 1 and 2 
Lys Ser 0,0255  pepsin A, cathepsin D, E and L, necepsin-1, calpain 1 and 2 
Ser Gln 0,0249 calpain 1 and 2, Cathepsin L and , matrix metallopeptidase-2 
 
 
Terminal 
C Residue 
Clivages 
Ratio 
Peptidases 
Gln Gly 0,1655 Cathepsin L,S,K 
Tyr Gly 0,0796 Pepsina A; Cathepsin D,L,S,B 
Ile Ala 0,0573 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Leu Ala 0,0419 Pepsin A, Cathepsin D and E 
Lys Ala 0,0393 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and 
X 
Pro Arg 0,0361 memapsin-1, angiotensin-converting enzyme-2, matrix metallopeptidase 2 and 
9 
Gln Ser 0,0350 pepsin A, gastricsin, Cathepsin B, L and S 
Ala Gly 0,0324 cathepsin L, S, K and B 
Gln Tyr 0,0292 Cathepsin E, L, S and B, matrix metallopeptidase-2 
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Vocal Chords SCC 
 
Terminal 
N 
Residue 
Clivages 
Ratio 
Peptidases 
Tyr Val 0,0175 pepsin A, rhizopuspepsin, cathepsin D and E, HIV-1 retropepsin 
Gln Gly 0,0159 Cathepsin L,S,K 
Lys Ala 0,0133 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and X 
Ile Ala 0,0122 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Tyr Gly 0,0117 Pepsina A; Cathepsin D,L,S,B 
Ile Met 0,0117 elastase-2, matrix metallopeptidase-2 
Met Val 0,0080 cathepsin B, D, E, L, S, rhizopuspepsin 
Leu Arg 0,0069 necepsin-1, presenilin 1, cathepsin D, E, L, H, matrix metallopeptidase-
2,carboxypeptidase E,M, N, U 
Phe Gly 0,0064 pepsin A and B, cathepsin D, E and L, necepsin 1, HIV-1 retropepsin,  
chymotrypsin A 
Leu Ala 0,0058 Pepsin A, Cathepsin D and E 
 
Terminal 
C Residue 
Clivages 
Ratio 
Peptidases 
Ile Ala 0,0308 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Lys Ala 0,0233 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and 
X 
Tyr Gly 0,0133 Pepsina A; Cathepsin D,L,S,B 
Ala His 0,0122 necepsin-2, Cathepsin L and S,  falcipain 2 and 3 
Ile Thr 0,0117 pepsin A, Cathepsin E, L and G, rhizopuspepsin,  elastase-2, ERAP2 
aminopeptidase 
Val Tyr 0,0111  falcipain2 and 3, matrix metallopeptidase 2 and 13, HtrA2 peptidase, elastase-
2 
Gln Gly 0,0095 Cathepsin L,S,K 
Pro Arg 0,0074 memapsin-1, angiotensin-converting enzyme-2, matrix metallopeptidase 2 and 
9 
Val Val 0,0069 thermolysin, leishmanolysin, elastase-2, lactocepin I and 3, cathepsin E, L1,  
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Mouth Floor SCC 
 
Terminal 
N 
Residue 
Clivages 
Ratio 
Peptidases 
Tyr Val 0,0133 pepsin A, rhizopuspepsin, cathepsin D and E, HIV-1 retropepsin 
Gln Gly 0,0111 Cathepsin L,S,K 
Met Val 0,0095 cathepsin B, D, E, L, S, rhizopuspepsin 
Lys Ala 0,0080 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and 
X 
Ile Ala 0,0074 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Arg Ser 0,0074 yapsin-1 and 3, cathepsin B, L, S, K, P, rhodesain, gingipain R 
Met Gly 0,0074 aspergillopepsin I, cathepsin B, L, S, K,  
Tyr Gly 0,0069 Pepsina A; Cathepsin D,L,S,B 
Ala Met 0,0058 matrix metallopeptidase-1, 2, 3, 9, 11, 13, meprin alpha subunit,  cathepsin B, 
D, E, L, S 
Ile Met 0,0058 elastase-2, matrix metallopeptidase-2 
 
 
Terminal 
C Residue 
Clivages 
Ratio 
Peptidases 
Ile Ala 0,0191 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Gln Gly 0,0133 Cathepsin L,S,K 
Lys Ala 0,0133 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and 
X 
Tyr Gly 0,0106 Pepsina A; Cathepsin D,L,S,B 
Leu Ala 0,0090 Pepsin A, Cathepsin D and E 
Ile Thr 0,0074 pepsin A, Cathepsin E, L and G, rhizopuspepsin,  elastase-2, ERAP2 
aminopeptidase 
Val Gly 0,0048 matrix metallopeptidase-9 and 12, elastase-2, HtrA2 peptidase, rhizopuspepsin 
Arg Gly 0,0048 rhizopuspepsin, memapsin-1, yapsin A, cathepsin B, L and K 
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Uvula and Soft Palate SCC 
 
Terminal 
N 
Residue 
Clivages 
Ratio 
Peptidases 
Ile Met 0,0164 elastase-2, matrix metallopeptidase-2 
Ile Ala 0,0111 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Tyr Val 0,0095 pepsin A, rhizopuspepsin, cathepsin D and E, HIV-1 retropepsin 
Arg Ser 0,0069 yapsin-1 and 3, cathepsin B, L, S, K, P, rhodesain, gingipain R 
Asn Ser 0,0058 aspergillopepsin, cathepsin, L, S and B 
Val His 0,0058 gastricsin, pepsin A,  falcipain-2, elastase-2, insulysin, cathepsin G 
Met Gly 0,0037 aspergillopepsin I, cathepsin B, L, S, K,  
Ala Met 0,0037 matrix metallopeptidase-1, 2, 3, 9, 11, 13, meprin alpha subunit,  cathepsin B, D, E, 
L, S 
Tyr Ser 0,0037 gastricsin, aspergilloglutamic peptidase, calpain-2, chymotrypsin A, cathepsin E, L 
and S 
Phe His 0,0032 phytepsin, cathepsin B, L and S, chymotrypsin A, carboxypeptidase A6, matrix 
metallopeptidase-2, 8 and 13 
 
Terminal 
C Residue 
Clivages 
Ratio 
Peptidases 
Ile Ala 0,0191 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Lys Ala 0,0133 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and 
X 
Ile Thr 0,0133 pepsin A, Cathepsin E, L and G, rhizopuspepsin,  elastase-2, ERAP2 
aminopeptidase 
Val His 0,0106 gastricsin, pepsin A,  falcipain-2, elastase-2, insulysin, cathepsin G 
Val Tyr 0,0090  falcipain2 and 3, matrix metallopeptidase 2 and 13, HtrA2 peptidase, elastase-
2 
Phe Tyr 0,0074 pepsin A and B, chymosin, cathepsin D and E  
Ala His 0,0058 necepsin-2, Cathepsin L and S,  falcipain 2 and 3 
Val Leu 0,0048 Pepsin A, Cathepsin D and E, rhizopuspepsin, necepsin 1 and 2 
Tyr Gly 0,0048 Pepsina A; Cathepsin D,L,S,B 
Lys Ser 0,0042  pepsin A, cathepsin D, E and L, necepsin-1, calpain 1 and 2 
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Tonsils SCC 
Terminal 
N 
Residue 
Clivages 
Ratio 
Peptidases 
Gln Gly 0,0329 Cathepsin L,S,K 
Gln Ser 0,0101 pepsin A, gastricsin, Cathepsin B, L and S 
Tyr Val 0,0074 pepsin A, rhizopuspepsin, cathepsin D and E, HIV-1 retropepsin 
Val Leu 0,0042 Pepsin A, Cathepsin D and E, rhizopuspepsin, necepsin 1 and 2 
Arg Lys 0,0037 pepsin A, Cathepsin D, E and L, omptin, peptidyl-Lys metallopeptidase 
Arg Pro 0,0037 bacilliform virus peptidase, aminopeptidase Ey, P1 and P2, trypsin 1 
Asp Leu 0,0037 pepsin A, cathepsin D and E, caspase 1, 3, 6, 7 and 8 
Leu Asp 0,0037 pepsin A, cathepsin D, E and S, necepsin-1, meprin beta subunit 
Pro Arg 0,0032 memapsin-1, angiotensin-converting enzyme-2, matrix metallopeptidase 2 and 9 
Lys Gly 0,0032 pepsin A, rhizopuspepsin, cathepsin L and S, falcipain 2 and 3, gingipain K,  matrix 
metallopeptidase 2, 9 and 13 
Ile Arg 0,0032 pepsin A, rhizopuspepsin, cathepsin L, calpain-1 and 2, elastase-2 
 
 
 
Terminal 
C 
Residue 
Clivages 
Ratio 
Peptidases 
Gln Gly 0,0393 Cathepsin L,S,K 
Leu Thr 0,0111 pepsin A and F, cathepsin D, E L and S, phytepsin, Rous sarcoma virus retropepsin, 
chymotrypsin A, granzyme A and M 
Lys Ala 0,0074 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and X 
Val Tyr 0,0064  falcipain2 and 3, matrix metallopeptidase 2 and 13, HtrA2 peptidase, elastase-2 
Val Leu 0,0058 Pepsin A, Cathepsin D and E, rhizopuspepsin, necepsin 1 and 2 
Pro Arg 0,0058 memapsin-1, angiotensin-converting enzyme-2, matrix metallopeptidase 2 and 9 
Tyr Gly 0,0048 Pepsina A; Cathepsin D,L,S,B 
Gln Ser 0,0042 pepsin A, gastricsin, Cathepsin B, L and S 
Ser Arg 0,0042 myeloblastin,  pepsin A, gastricsin, memapsin-1,  
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Oropharyngeal SCC 
 
Terminal 
N 
Residue 
Clivages 
Ratio 
Peptidases 
Val Arg 0,0398 DegP peptidase; Cathepsin L; chymosin;rhizopuspepsin 
Met Asn 0,0350 granzyme M, meprin beta subunit, Cathepsin B, E, L, K, S 
Lys Ala 0,0308 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and 
X 
Ile Met 0,0239 elastase-2, matrix metallopeptidase-2 
Ile Ala 0,0143 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Tyr Val 0,0143 pepsin A, rhizopuspepsin, cathepsin D and E, HIV-1 retropepsin 
Leu Ala 0,0138 Pepsin A, Cathepsin D and E 
Tyr Gly 0,0133 Pepsina A; Cathepsin D,L,S,B 
Phe Gly 0,0106 pepsin A and B, cathepsin D, E and L, necepsin 1, HIV-1 retropepsin,  
chymotrypsin A 
Val Leu 0,0085 Pepsin A, Cathepsin D and E, rhizopuspepsin, necepsin 1 and 2 
 
 
 
Terminal 
C 
Residue 
Clivages 
Ratio 
Peptidases 
Ile Ala 0,0679 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Lys Ala 0,0377 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and X 
Lys Ser 0,0175  pepsin A, cathepsin D, E and L, necepsin-1, calpain 1 and 2 
Tyr Gly 0,0164 Pepsina A; Cathepsin D,L,S,B 
Ala His 0,0164 necepsin-2, Cathepsin L and S,  falcipain 2 and 3 
Ala Gly 0,0143 cathepsin L, S, K and B 
Val Leu 0,0133 Pepsin A, Cathepsin D and E, rhizopuspepsin, necepsin 1 and 2 
Tyr Thr 0,0133 SplA peptidase ({Staphylococcus aureus}), chymotrypsin A, meprin alpha 
subunit, rhizopuspepsin, 
Arg Ile 0,0111 matrix metallopeptidase 2, 12 and 13,  kallikrein-related peptidase 5, 12 and 14, 
cathepsin E, P and H 
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Nasopharynx 
 
Terminal 
N Residue 
Clivages 
Ratio 
Peptidases 
Ile Ala 0,0111 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Gln Gly 0,0095 Cathepsin L,S,K 
Tyr Gly 0,0085 Pepsina A; Cathepsin D,L,S,B 
Tyr Val 0,0074 pepsin A, rhizopuspepsin, cathepsin D and E, HIV-1 retropepsin 
Tyr Ser 0,0074 gastricsin, aspergilloglutamic peptidase, calpain-2, chymotrypsin A, cathepsin E, L 
and S 
Leu Ala 0,0064 Pepsin A, Cathepsin D and E 
Cys Val 0,0048 cathepsin B, E and L,  necepsin 1 and 2, thermolysin, bacillolysin, caspase-1 
Ala Ala 0,0048 pepsin A, cathepsin B, E, L, S and K, matrix metallopeptidase 2, 3, 7, 9, 11 and 12 
Lys Ala 0,0048 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and X 
Lys Leu 0,0048 falcipain 2 and 3,  calpain 1 and 2, bacillolysin, trypsin 1, membrane-type matrix 
metallopeptidase 1, 3 ,4 and 6, matrix metallopeptidase2, 3, 7, 9 and 12 
 
Terminal 
C 
Residue 
Clivages 
Ratio 
Peptidases 
Lys Ala 0,0164 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and 
X 
Lys Ser 0,0122  pepsin A, cathepsin D, E and L, necepsin-1, calpain 1 and 2 
Ile Ala 0,0111 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Gln Gly 0,0064 Cathepsin L,S,K 
Tyr Gly 0,0053 Pepsina A; Cathepsin D,L,S,B 
Pro Arg 0,0053 memapsin-1, angiotensin-converting enzyme-2, matrix metallopeptidase 2 and 
9 
Ile Thr 0,0048 pepsin A, Cathepsin E, L and G, rhizopuspepsin,  elastase-2, ERAP2 
aminopeptidase 
Ala Tyr 0,0042 cathepsin B, D and E, plasmepsin-1, pepsin A, matrix metallopeptidase 2, 3, 7, 
9 and 12 
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Hypopharyngeal SCC 
 
Terminal 
N 
Residue 
Clivages 
Ratio 
Peptidases 
Gln Gly 0,0202 Cathepsin L,S,K 
Ser Gln 0,0048 calpain 1 and 2, Cathepsin L and , matrix metallopeptidase-2 
Pro Pro 0,0048 Cathepsin L1 and L3, lactocepin I, calpain 1 and 2 
Gln Pro 0,0032 lactocepin I and 3, elastase-2,  thermolysin 
Arg Gly 0,0027 rhizopuspepsin, memapsin-1, yapsin A, cathepsin B, L and K 
Lys His 0,0021 rhizopuspepsin, syncephapepsin, aspergillopepsin I, trypsin 1, lysyl endopeptidase 
(bacteria) 
Phe His 0,0021 phytepsin, cathepsin B, L and S, chymotrypsin A, carboxypeptidase A6, matrix 
metallopeptidase-2, 8 and 13 
Arg Lys 0,0016 pepsin A, Cathepsin D, E and L, omptin, peptidyl-Lys metallopeptidase 
Arg Ser 0,0016 yapsin-1 and 3, cathepsin B, L, S, K, P, rhodesain, gingipain R 
Pro Arg 0,0016 memapsin-1, angiotensin-converting enzyme-2, matrix metallopeptidase 2 and 9 
Gly Arg 0,0016 necepsin-1, cathepsin B, S, L and X, carboxypeptidase B, E, M, N, and U 
Tyr Gly 0,0016 Pepsina A; Cathepsin D,L,S,B 
Phe Gly 0,0016 pepsin A and B, cathepsin D, E and L, necepsin 1, HIV-1 retropepsin,  
chymotrypsin A 
 
Terminal 
C Residue 
Clivages 
Ratio 
Peptidases 
Gln Gly 0,0186 Cathepsin L,S,K 
Tyr Gly 0,0069 Pepsina A; Cathepsin D,L,S,B 
Arg Gly 0,0032 rhizopuspepsin, memapsin-1, yapsin A, cathepsin B, L and K 
Pro Arg 0,0027 memapsin-1, angiotensin-converting enzyme-2, matrix metallopeptidase 2 and 9 
Ser Arg 0,0027 myeloblastin,  pepsin A, gastricsin, memapsin-1,  
Pro Gln 0,0027  ADAM8 peptidase, ADAM10 peptidase, ADAM19 peptidase, prolyl oligopeptidase, 
membrane-type matrix metallopeptidase 1, 2, 3, 4 and 6, matrix metallopeptidase 2, 8, 
9 and 12 
Gln Pro 0,0027 lactocepin I and 3, elastase-2,  thermolysin 
Gln Tyr 0,0027 Cathepsin E, L, S and B, matrix metallopeptidase-2 
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Nostrils 
 
Terminal 
N Residue 
Clivages 
Ratio 
Peptidases 
Tyr Val 0,0117 pepsin A, rhizopuspepsin, cathepsin D and E, HIV-1 retropepsin 
Ile Met 0,0117 elastase-2, matrix metallopeptidase-2 
Gln Gly 0,0090 Cathepsin L,S,K 
Tyr Gly 0,0069 Pepsina A; Cathepsin D,L,S,B 
Asp Gly 0,0058 pepsin A; Cathepsin B, Caspase 1, HIV-1 retropepsin 
Met Asn 0,0058 granzyme M, meprin beta subunit, Cathepsin B, E, L, K, S 
Met Gly 0,0058 aspergillopepsin I, cathepsin B, L, S, K,  
Ile Ala 0,0058 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Lys Ala 0,0058 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L 
and X 
Val His 0,0048 gastricsin, pepsin A,  falcipain-2, elastase-2, insulysin, cathepsin G 
 
 
Terminal 
C Residue 
Clivages 
Ratio 
Peptidases 
Ile Ala 0,0233 Pepsin A, Cathepsin E, L, S; rhizopuspepsin,aspergillopepsin I  
Pro Arg 0,0122 memapsin-1, angiotensin-converting enzyme-2, matrix metallopeptidase 2 and 
9 
Lys Ala 0,0122 Pepsin A, penicillopepsin, rhizopuspepsin, aspergillopepsin I, cathepsin L and 
X 
Leu Ala 0,0080 Pepsin A, Cathepsin D and E 
Gln Gly 0,0074 Cathepsin L,S,K 
Tyr Gly 0,0064 Pepsina A; Cathepsin D,L,S,B 
Ile Thr 0,0058 pepsin A, Cathepsin E, L and G, rhizopuspepsin,  elastase-2, ERAP2 
aminopeptidase 
Val Tyr 0,0048  falcipain2 and 3, matrix metallopeptidase 2 and 13, HtrA2 peptidase, elastase-
2 
Arg Asp 0,0042 granzyme A, trypsin 1,  meprin alpha subunit, meprin beta subunit 
 
 
 
 
 
 
  
   105 
Number of peptide sequences for each individue 
Control nº of repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
C1 52 79 131 
C2 42 99 141 
C3 27 60 87 
C4 23 55 78 
C5 29 106 135 
C6 5 34 39 
C7 2 28 30 
C8 42 70 112 
C9 8 68 76 
C10 18 39 57 
Average 24,8 63,8 88,6 
STDev 16,9 26,2 40,0 
 
 
Vocal Chords 
(patient) 
nº of 
repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
1 11 43 54 
2 100 77 177 
3 35 51 86 
4 11 70 81 
Average 39,2 60,2 99,5 
STDev 42,0 15,9 53,5 
 
 
Larynx 
(patient) 
nº of repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
5 18 108 126 
6 23 71 94 
7 76 83 159 
8 46 39 85 
9 4 74 78 
10 43 76 119 
11 10 69 79 
12 40 36 76 
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13 73 71 144 
14 36 84 120 
15 21 15 36 
16 49 156 205 
17 49 25 74 
18 6 28 34 
19 35 107 142 
20 10 61 71 
21 31 58 89 
22 11 54 65 
23 10 30 40 
24 11 50 61 
Average 30,1 64,75 94,85 
STDev 21,4 33,6 44,3 
 
Tongue 
(patient) 
nº of repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
25 49 110 149 
 
Oropharynx 
(patient) 
nº of repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
26 89 108 197 
27 3 49 52 
28 60 46 106 
29 144 140 284 
Average 74 85,75 159,75 
STDev 58,7 46,0 102,1 
 
Mouth floor 
(patient) 
nº of repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
30 78 100 178 
31 17 114 131 
Average 47,5 107 154,5 
STDev 43,1 9,8 33,2 
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Uvula and 
Soft Palate 
(patient) 
nº of repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
32 66 44 110 
 
Tonsil 
(patient) 
nº of repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
33 51 123 174 
34 5 40 45 
35 40 34 74 
Average 32 65,6 97,6 
STDev 24,03 49,7 67,64 
 
Pharynx 
(patient) 
nº of repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
36 13 97 110 
 
Pharyngolarynx 
(patient) 
nº of 
repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
37 95 160 255 
38 81 167 248 
Average 88 163,5 251,5 
STDev 9,8 4,9 4,9 
 
Hypopharynx 
(patient) 
nº of 
repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
39 2 6 8 
40 29 99 128 
Average 15,5 52,5 68 
STDev 19,0 65,7 84,8 
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Nostrils 
(patient) 
nº of repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
41 69 313 382 
42 8 44 52 
43 51 18 69 
Average 42,6 125 167,6 
STDev 31,3 163,3 185,8 
 
 
Nasopharynx 
(patient) 
 
nº of 
repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
44 66 95 161 
 
Control n=10 repeated 
sequences  
unique 
sequences 
total sequences 
Average 24,8 63,8 88,6 
STDev 16,9 26,2 40,01 
 
 
Larynx group 
n=24 
repeated 
sequences  
unique 
sequences 
total sequences 
Average  31,6 64 95,6 
STDev 24,9 31,1 44,7 
 
Pharynx 
and Oral 
Cavity 
Group 
n=16 
 repeated 
sequences  
unique 
sequences 
total sequences 
Average 51,375 89,8125 140,5625 
STDev 39,9 47,8 78,8 
 
 
Nasopharynx 
and Nostrils 
n=4 
nº of repeated 
sequences  
nº of unique 
sequences 
nº of total 
sequences 
Average 48,5 117,5 166 
STDev 28,1 134,2 151,7 
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